The University of Chicago Header Logo

Thomas F. Gajewski

InstitutionUniversity of Chicago
AddressChicago IL 60637
vCardDownload vCard

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Ascierto PA, Agarwala SS, Warner AB, Ernstoff MS, Fox BA, Gajewski TF, Galon J, Garbe C, Gastman BR, Gershenwald JE, Kalinski P, Krogsgaard M, Leidner RS, Lo RS, Menzies AM, Michielin O, Poulikakos PI, Weber JS, Caracò C, Osman I, Puzanov I, Thurin M. Perspectives in Melanoma: meeting report from the Melanoma Bridge (December 1st-3rd, 2022-Naples, Italy). J Transl Med. 2023 07 28; 21(1):508. PMID: 37507765; PMCID: PMC10375730.
      Citations: 1     Fields:    Translation:Humans
    2. Coveler AL, Smith DC, Phillips T, Curti BD, Goel S, Mehta AN, Kuzel TM, Markovic SN, Rixe O, Bajor DL, Gajewski TF, Gutierrez M, Lee HJ, Gopal AK, Caimi P, Heath EI, Thompson JA, Ansari S, Jacquemont C, Topletz-Erickson A, Zhou P, Schmitt MW, Grilley-Olson JE. Phase 1 dose-escalation study of SEA-CD40: a non-fucosylated CD40 agonist, in advanced solid tumors and lymphomas. J Immunother Cancer. 2023 06; 11(6). PMID: 37385724; PMCID: PMC10314623.
      Citations: 1     Fields:    Translation:HumansCTClinical Trials
    3. Ferguson R, Chat V, Morales L, Simpson D, Monson KR, Cohen E, Zusin S, Madonna G, Capone M, Simeone E, Pavlick A, Luke JJ, Gajewski TF, Osman I, Ascierto P, Weber J, Kirchhoff T. Germline immunomodulatory expression quantitative trait loci (ieQTLs) associated with immune-related toxicity from checkpoint inhibition. Eur J Cancer. 2023 08; 189:112923. PMID: 37301715.
      Citations:    Fields:    Translation:Humans
    4. Mathias K, Rouhani S, Olson D, Bass AR, Gajewski TF, Reid P. Association Between Rheumatic Autoantibodies and Immune-Related Adverse Events. Oncologist. 2023 05 08; 28(5):440-448. PMID: 36595378; PMCID: PMC10166164.
      Citations: 2     Fields:    Translation:Humans
    5. Reschke R, Gajewski TF. Tissue-resident memory T cells in immune-related adverse events: friend or foe? Oncoimmunology. 2023; 12(1):2197358. PMID: 37035636; PMCID: PMC10078118.
      Citations:    Fields:    Translation:HumansCells
    6. MacDonald ME, Weathered RK, Stewart EC, Magold AI, Mukherjee A, Gurbuxani S, Smith H, McMullen P, Mueller J, Husain AN, Salles CM, Briquez PS, Rouhani SJ, Yu J, Trujillo J, Pyzer AR, Gajewski TF, Sperling AI, Kilarski WW, Swartz MA. Lymphatic coagulation and neutrophil extracellular traps in lung-draining lymph nodes of COVID-19 decedents. Blood Adv. 2022 12 27; 6(24):6249-6262. PMID: 35977099; PMCID: PMC9394105.
      Citations: 2     Fields:    Translation:AnimalsCells
    7. Spurr LF, Martinez CA, Kang W, Chen M, Zha Y, Hseu R, Gutiontov SI, Turchan WT, Lynch CM, Pointer KB, Chang P, Murgu S, Husain AN, Cody B, Vokes EE, Bestvina CM, Patel JD, Diehn M, Gajewski TF, Weichselbaum RR, Chmura SJ, Pitroda SP. Highly aneuploid non-small cell lung cancer shows enhanced responsiveness to concurrent radiation and immune checkpoint blockade. Nat Cancer. 2022 Nov 28. PMID: 36443406.
      Citations: 12     Fields:    
    8. Hayes DF, Herbst RS, Myles JL, Topalian SL, Yohe SL, Aronson N, Bellizzi AM, Basu Roy U, Bradshaw G, Edwards RH, El-Gabry EA, Elvin J, Gajewski TF, McShane LM, Oberley M, Philip R, Rimm DL, Rosenbaum JN, Rubin EH, Schlager L, Sherwood SW, Stewart M, Taube JM, Thurin M, Vasalos P, Laser J. Proceedings From the ASCO/College of American Pathologists Immune Checkpoint Inhibitor Predictive Biomarker Summit. JCO Precis Oncol. 2022 11; 6:e2200454. PMID: 36446042; PMCID: PMC10530621.
      Citations: 2     Fields:    Translation:Humans
    9. Briquez PS, Rouhani SJ, Yu J, Pyzer AR, Trujillo J, Dugan HL, Stamper CT, Changrob S, Sperling AI, Wilson PC, Gajewski TF, Hubbell JA, Swartz MA. Severe COVID-19 induces autoantibodies against angiotensin II that correlate with blood pressure dysregulation and disease severity. Sci Adv. 2022 10 07; 8(40):eabn3777. PMID: 36206332; PMCID: PMC9544317.
      Citations: 15     Fields:    Translation:HumansCells
    10. Reschke R, Shapiro JW, Yu J, Rouhani SJ, Olson DJ, Zha Y, Gajewski TF. Checkpoint Blockade-Induced Dermatitis and Colitis Are Dominated by Tissue-Resident Memory T Cells and Th1/Tc1 Cytokines. Cancer Immunol Res. 2022 10 04; 10(10):1167-1174. PMID: 35977003; PMCID: PMC9530647.
      Citations: 10     Fields:    Translation:HumansCells
    11. Ascierto PA, Agarwala SS, Blank C, Carvajal RD, Ernstoff MS, Ferrone S, Fox BA, Gajewski TF, Garbe C, Grob JJ, Hamid O, Krogsgaard M, Lo RS, Lund AW, Madonna G, Michielin O, Neyns B, Osman I, Peters S, Poulikakos PI, Quezada SA, Reinfeld B, Zitvogel L, Puzanov I, Thurin M, Caracò C. Perspectives in Melanoma: meeting report from the Melanoma Bridge (December 2nd - 4th, 2021, Italy). J Transl Med. 2022 09 04; 20(1):391. PMID: 36058945; PMCID: PMC9440864.
      Citations:    Fields:    Translation:HumansPHPublic Health
    12. Chesney JA, Ribas A, Long GV, Kirkwood JM, Dummer R, Puzanov I, Hoeller C, Gajewski TF, Gutzmer R, Rutkowski P, Demidov L, Shin SJ, Ferrucci PF, Haydon A, Hyngstrom J, Haferkamp S, Guilera JM, Rapoport BL, VanderWalde A, Diede SJ, Anderson JR, Treichel S, Chan EL, Bhatta S, Gansert J, Hodi FS, Gogas H, van Thienen JV, Arenberger P. Randomized, Double-Blind, Placebo-Controlled, Global Phase III Trial of Talimogene Laherparepvec Combined With Pembrolizumab for Advanced Melanoma. J Clin Oncol. 2023 01 20; 41(3):528-540. PMID: 35998300; PMCID: PMC9870217.
      Citations: 42     Fields:    Translation:HumansCellsCTClinical Trials
    13. Reschke R, Gajewski TF. CXCL9 and CXCL10 bring the heat to tumors. Sci Immunol. 2022 07 22; 7(73):eabq6509. PMID: 35867802.
      Citations: 30     Fields:    Translation:Cells
    14. Higgs EF, Flood BA, Pyzer AR, Rouhani SJ, Trujillo JA, Gajewski TF. Insights from a Rapidly Implemented COVID-19 Biobank Using Electronic Consent and Informatics Tools. Biopreserv Biobank. 2023 Apr; 21(2):166-175. PMID: 35771982; PMCID: PMC10125396.
      Citations:    Fields:    Translation:HumansPHPublic Health
    15. Higgs EF, Bao R, Hatogai K, Gajewski TF. Wilms tumor reveals DNA repair gene hyperexpression is linked to lack of tumor immune infiltration. J Immunother Cancer. 2022 06; 10(6). PMID: 35705315; PMCID: PMC9204399.
      Citations: 2     Fields:    Translation:HumansCells
    16. Rouhani SJ, Yu J, Olson D, Zha Y, Pezeshk A, Cabanov A, Pyzer AR, Trujillo J, Derman BA, O'Donnell P, Jakubowiak A, Kindler HL, Bestvina C, Gajewski TF. Antibody and T cell responses to COVID-19 vaccination in patients receiving anticancer therapies. J Immunother Cancer. 2022 06; 10(6). PMID: 35732350; PMCID: PMC9226983.
      Citations: 5     Fields:    Translation:HumansCellsPHPublic Health
    17. Matson V, Gajewski TF. Dietary modulation of the gut microbiome as an immunoregulatory intervention. Cancer Cell. 2022 03 14; 40(3):246-248. PMID: 35290783.
      Citations: 6     Fields:    Translation:Humans
    18. Mojtahed SA, Boyer NR, Rao SA, Gajewski TF, Tseng J, Turaga KK. ASO Visual Abstract: Cost-Effectiveness Analysis of Adjuvant Therapy for BRAF-Mutant Resected Stage 3 Melanoma in Medicare Patients. Ann Surg Oncol. 2021 Dec; 28(Suppl 3):576. PMID: 34355335.
    19. Rouhani SJ, Trujillo JA, Pyzer AR, Yu J, Fessler J, Cabanov A, Higgs EF, Cron KR, Zha Y, Lu Y, Bloodworth JC, Abasiyanik MF, Okrah S, Flood BA, Hatogai K, Leung MY, Pezeshk A, Kozloff L, Reschke R, Strohbehn GW, Chervin CS, Kumar M, Schrantz S, Madariaga ML, Beavis KG, Yeo KJ, Sweis RF, Segal J, Tay S, Izumchenko E, Mueller J, Chen LS, Gajewski TF. Severe COVID-19 infection is associated with aberrant cytokine production by infected lung epithelial cells rather than by systemic immune dysfunction. Res Sq. 2021 Nov 24. PMID: 34845442; PMCID: PMC8629200.
      Citations: 3     
    20. Briquez PS, Rouhani SJ, Yu J, Pyzer AR, Trujillo J, Dugan HL, Stamper CT, Changrob S, Sperling AI, Wilson PC, Gajewski TF, Hubbell JA, Swartz MA. SARS-CoV-2 infection induces cross-reactive autoantibodies against angiotensin II. medRxiv. 2021 Nov 02. PMID: 34751272; PMCID: PMC8575143.
    21. Reschke R, Yu J, Flood B, Higgs EF, Hatogai K, Gajewski TF. Immune cell and tumor cell-derived CXCL10 is indicative of immunotherapy response in metastatic melanoma. J Immunother Cancer. 2021 09; 9(9). PMID: 34593622; PMCID: PMC8487215.
      Citations: 24     Fields:    Translation:Humans
    22. Gajewski TF. Frank W. Fitch (1929-2021). Nat Immunol. 2021 Jul; 22(7):799. PMID: 34099920.
    23. Bao R, Spranger S, Hernandez K, Zha Y, Pytel P, Luke JJ, Gajewski TF, Volchenboum SL, Cohn SL, Desai AV. Immunogenomic determinants of tumor microenvironment correlate with superior survival in high-risk neuroblastoma. J Immunother Cancer. 2021 07; 9(7). PMID: 34272305; PMCID: PMC8287618.
      Citations: 15     Fields:    Translation:Humans
    24. Ascierto PA, Blank C, Dummer R, Ernstoff MS, Ferrone S, Fox BA, Gajewski TF, Garbe C, Hwu P, Kalinski P, Krogsgaard M, Lo RS, Luke JJ, Neyns B, Postow MA, Quezada SA, Teng MWL, Trinchieri G, Testori A, Osman I, Puzanov I, Thurin M, Caracò C. Perspectives in Melanoma: meeting report from the Melanoma Bridge (December 3rd-5th, 2020, Italy). J Transl Med. 2021 06 30; 19(1):278. PMID: 34193182; PMCID: PMC8243582.
      Citations: 1     Fields:    Translation:Humans
    25. Mojtahed SA, Boyer NR, Rao SA, Gajewski TF, Tseng J, Turaga KK. Cost-Effectiveness Analysis of Adjuvant Therapy for BRAF-Mutant Resected Stage III Melanoma in Medicare Patients. Ann Surg Oncol. 2021 Dec; 28(13):9039-9047. PMID: 34129153.
      Citations: 1     Fields:    Translation:Humans
    26. Abasiyanik MF, Flood B, Lin J, Ozcan S, Rouhani SJ, Pyzer A, Trujillo J, Zhen C, Wu P, Jumic S, Wang A, Gajewski TF, Wang P, Hartley M, Ameti B, Niemiec R, Fernando M, Mishra V, Savage P, Aydogan B, Bethel C, Matushek S, Beavis KG, Agrawal N, Segal J, Tay S, Izumchenko E. Sensitive detection and quantification of SARS-CoV-2 in saliva. Sci Rep. 2021 06 14; 11(1):12425. PMID: 34127708; PMCID: PMC8203799.
      Citations: 20     Fields:    Translation:HumansCells
    27. Olson DJ, Eroglu Z, Brockstein B, Poklepovic AS, Bajaj M, Babu S, Hallmeyer S, Velasco M, Lutzky J, Higgs E, Bao R, Carll TC, Labadie B, Krausz T, Zha Y, Karrison T, Sondak VK, Gajewski TF, Khushalani NI, Luke JJ. Pembrolizumab Plus Ipilimumab Following Anti-PD-1/L1 Failure in Melanoma. J Clin Oncol. 2021 08 20; 39(24):2647-2655. PMID: 33945288; PMCID: PMC8376314.
      Citations: 42     Fields:    Translation:HumansCTClinical Trials
    28. Vining CC, Hsu PJ, Miller A, Olson DJ, Gajewski TF, Pytel P, Bauer BS, Millis MJ, Roggin KK. Novel response to neoadjuvant anti-PD1 therapy for a patient with retrocaval melanotic schwannoma. Melanoma Res. 2021 02 01; 31(1):92-97. PMID: 33323721; PMCID: PMC7755705.
      Citations: 3     Fields:    Translation:Humans
    29. Strohbehn GW, Heiss BL, Rouhani SJ, Trujillo JA, Yu J, Kacew AJ, Higgs EF, Bloodworth JC, Cabanov A, Wright RC, Koziol AK, Weiss A, Danahey K, Karrison TG, Edens CC, Bauer Ventura I, Pettit NN, Patel BK, Pisano J, Strek ME, Gajewski TF, Ratain MJ, Reid PD. COVIDOSE: A Phase II Clinical Trial of Low-Dose Tocilizumab in the Treatment of Noncritical COVID-19 Pneumonia. Clin Pharmacol Ther. 2021 03; 109(3):688-696. PMID: 33210302; PMCID: PMC7753375.
      Citations: 31     Fields:    Translation:HumansCellsCTClinical Trials
    30. Abasiyanik MF, Flood B, Lin J, Ozcan S, Rouhani SJ, Pyzer A, Trujillo J, Zhen C, Wu P, Jumic S, Wang A, Gajewski TF, Wang P, Hartley M, Ameti B, Niemiec R, Fernando M, Aydogan B, Bethel C, Matushek S, Beavis KG, Agrawal N, Segal J, Tay S, Izumchenko E. Sensitive detection and quantification of SARS-CoV-2 in saliva. medRxiv. 2020 Dec 07. PMID: 33330880; PMCID: PMC7743089.
      Citations: 6     
    31. Matson V, Chervin CS, Gajewski TF. Cancer and the Microbiome-Influence of the Commensal Microbiota on Cancer, Immune Responses, and Immunotherapy. Gastroenterology. 2021 01; 160(2):600-613. PMID: 33253684; PMCID: PMC8409239.
      Citations: 99     Fields:    Translation:HumansAnimals
    32. Soto Chervin C, Gajewski TF. Microbiome-based interventions: therapeutic strategies in cancer immunotherapy. Immunooncol Technol. 2020 Dec; 8:12-20. PMID: 35757563; PMCID: PMC9216398.
      Citations: 4     
    33. Luke JJ, Onderdonk BE, Bhave SR, Karrison T, Lemons JM, Chang P, Zha Y, Carll T, Krausz T, Huang L, Martinez C, Janisch LA, Hseu RD, Moroney JW, Patel JD, Khodarev NN, Salama JK, Ott PA, Fleming GF, Gajewski TF, Weichselbaum RR, Pitroda SP, Chmura SJ. Improved Survival Associated with Local Tumor Response Following Multisite Radiotherapy and Pembrolizumab: Secondary Analysis of a Phase I Trial. Clin Cancer Res. 2020 12 15; 26(24):6437-6444. PMID: 33028595; PMCID: PMC8561652.
      Citations: 18     Fields:    Translation:HumansCTClinical Trials
    34. Koss B, Shields BD, Taylor EM, Storey AJ, Byrum SD, Gies AJ, Washam CL, Choudhury SR, Hyun Ahn J, Uryu H, Williams JB, Krager KJ, Chiang TC, Mackintosh SG, Edmondson RD, Aykin-Burns N, Gajewski TF, Wang GG, Tackett AJ. Epigenetic Control of Cdkn2a.Arf Protects Tumor-Infiltrating Lymphocytes from Metabolic Exhaustion. Cancer Res. 2020 11 01; 80(21):4707-4719. PMID: 33004350; PMCID: PMC7642172.
      Citations: 12     Fields:    Translation:AnimalsCells
    35. Ascierto PA, Puzanov I, Agarwala SS, Blank C, Carvajal RD, Demaria S, Dummer R, Ernstoff M, Ferrone S, Fox BA, Gajewski TF, Hwu P, Lo RS, Long GV, Luke JJ, Osman I, Postow MA, Sullivan RJ, Taube JM, Trinchieri G, Zarour HM, Thurin M, Garbe C, Caracò C. Perspectives in melanoma: meeting report from the "Melanoma Bridge" (December 5th-7th, 2019, Naples, Italy). J Transl Med. 2020 09 07; 18(1):346. PMID: 32894202; PMCID: PMC7487701.
      Citations: 2     Fields:    Translation:Humans
    36. Gajewski TF, Higgs EF. Immunotherapy with a sting. Science. 2020 08 21; 369(6506):921-922. PMID: 32820113.
      Citations: 15     Fields:    Translation:Humans
    37. Gajewski TF, Cron KR. cDC1 dysregulation in cancer: An opportunity for intervention. J Exp Med. 2020 08 03; 217(8). PMID: 32697286; PMCID: PMC7398176.
      Citations: 4     Fields:    Translation:HumansCells
    38. Strohbehn GW, Heiss BL, Rouhani SJ, Trujillo JA, Yu J, Kacew AJ, Higgs EF, Bloodworth JC, Cabanov A, Wright RC, Koziol A, Weiss A, Danahey K, Karrison TG, Edens CC, Ventura IB, Pettit NN, Patel B, Pisano J, Strek ME, Gajewski TF, Ratain MJ, Reid PD. COVIDOSE: Low-dose tocilizumab in the treatment of Covid-19. medRxiv. 2020 Jul 26. PMID: 32743594; PMCID: PMC7386518.
      Citations: 1     
    39. Gajewski TF. Strategies to overcome resistance to PD-1 inhibitors. Clin Adv Hematol Oncol. 2020 May; 18(5):270-272. PMID: 32628654.
      Citations:    Fields:    Translation:Humans
    40. Ascierto PA, Fox BA, Urba WJ, Anderson AC, Atkins MB, Borden EC, Brahmer JR, Butterfield LH, Cesano A, Chen DC, de Gruijl TD, Dillman RO, Drake CG, Emens LA, Gajewski TF, Gulley JL, Stephen Hodi FJ, Hwu P, Kaufman D, Kaufman HL, Lotze MT, McNeel DG, Margolin KM, Marincola FM, Mastrangelo MJ, Maus MV, Parkinson DR, Romero PJ, Sondel PM, Spranger S, Sznol M, Weiner GJ, Wigginton JM, Weber JS. Insights from immuno-oncology: the Society for Immunotherapy of Cancer Statement on access to IL-6-targeting therapies for COVID-19. J Immunother Cancer. 2020 04; 8(1). PMID: 32300051; PMCID: PMC7204613.
      Citations: 44     Fields:    Translation:HumansCellsPHPublic Health
    41. Olson DJ, Rajagopal P, Tjota MY, Venkataraman G, Luke JJ, Gajewski TF. A case of dual-mechanism immune-related anaemia in a patient with metastatic melanoma treated with nivolumab and ipilimumab. J Immunother Cancer. 2020 03; 8(1). PMID: 32169870; PMCID: PMC7069276.
      Citations: 3     Fields:    Translation:Humans
    42. Williams JB, Li S, Higgs EF, Cabanov A, Wang X, Huang H, Gajewski TF. Tumor heterogeneity and clonal cooperation influence the immune selection of IFN-?-signaling mutant cancer cells. Nat Commun. 2020 01 30; 11(1):602. PMID: 32001684; PMCID: PMC6992737.
      Citations: 52     Fields:    Translation:HumansAnimalsCells
    43. Pearson ADJ, Lesa G, Diede SJ, Weiner S, Anderson J, Gray J, Geoerger B, Minard-Colin V, Marshall LV, Smith M, Sondel P, Bajars M, Baldazzi C, Barry E, Blackman S, Blanc P, Capdeville R, Caron H, Cole PD, Donoghue M, Elgadi M, Gajewski T, Galluzzo S, Ilaria R, Karres D, Kieran M, Ligas F, Lowy I, Meyers M, Oprea C, Peddareddigari VGR, Sterba J, Stockman PK, Suenaert P, Tabori U, van Tilburg C, Yancey T, Weigel B, Norga K, Reaman G, Vassal G, Rossig C, Jiménez JC, Demolis P, Jenkner A. ACCELERATE and European Medicines Agency Paediatric Strategy Forum for medicinal product development of checkpoint inhibitors for use in combination therapy in paediatric patients. Eur J Cancer. 2020 03; 127:52-66. PMID: 31986450.
      Citations: 22     Fields:    Translation:Humans
    44. Gajewski TF, Fessler J. PAK4 as a cancer immune-evasion target. Nat Cancer. 2020 01; 1(1):18-19. PMID: 35121838.
      Citations: 4     Fields:    Translation:Humans
    45. Stein JE, Soni A, Danilova L, Cottrell TR, Gajewski TF, Hodi FS, Bhatia S, Urba WJ, Sharfman WH, Wind-Rotolo M, Edwards R, Lipson EJ, Taube JM. Major pathologic response on biopsy (MPRbx) in patients with advanced melanoma treated with anti-PD-1: evidence for an early, on-therapy biomarker of response. Ann Oncol. 2019 Apr; 30(4):589-596. PMID: 31987276.
    46. Ribas A, Daud A, Pavlick AC, Gonzalez R, Lewis KD, Hamid O, Gajewski TF, Puzanov I, Wongchenko M, Rooney I, Hsu JJ, Yan Y, Park E, McArthur GA. Extended 5-Year Follow-up Results of a Phase Ib Study (BRIM7) of Vemurafenib and Cobimetinib in BRAF-Mutant Melanoma. Clin Cancer Res. 2020 01 01; 26(1):46-53. PMID: 31732523; PMCID: PMC6942621.
      Citations: 17     Fields:    Translation:HumansCTClinical Trials
    47. Trujillo JA, Luke JJ, Zha Y, Segal JP, Ritterhouse LL, Spranger S, Matijevich K, Gajewski TF. Secondary resistance to immunotherapy associated with ß-catenin pathway activation or PTEN loss in metastatic melanoma. J Immunother Cancer. 2019 11 08; 7(1):295. PMID: 31703593; PMCID: PMC6839232.
      Citations: 63     Fields:    Translation:HumansCells
    48. Ascierto PA, Agarwala SS, Botti G, Budillon A, Davies MA, Dummer R, Ernstoff M, Ferrone S, Formenti S, Gajewski TF, Garbe C, Hamid O, Lo RS, Luke JJ, Michielin O, Palmieri G, Marincola FM, Masucci G, Thurin M, Puzanov I, Zitvogel L, Caracò C. Perspectives in melanoma: meeting report from the Melanoma Bridge (November 29th-1 December 1st, 2018, Naples, Italy). J Transl Med. 2019 07 22; 17(1):234. PMID: 31331337; PMCID: PMC6647284.
      Citations: 6     Fields:    Translation:HumansCells
    49. Flood BA, Higgs EF, Li S, Luke JJ, Gajewski TF. STING pathway agonism as a cancer therapeutic. Immunol Rev. 2019 07; 290(1):24-38. PMID: 31355488; PMCID: PMC6814203.
      Citations: 127     Fields:    Translation:HumansAnimalsCells
    50. Long GV, Hamid O, Gajewski TF, Caglevic C, Dalle S, Carlino MS, Kim TM, Demidov L, Robert C, Larkin J, Anderson JR, Maleski J, Jones M, Diede SJ, Mitchell TC, Dummer R, Arance A, Grob JJ. Epacadostat plus pembrolizumab versus placebo plus pembrolizumab in patients with unresectable or metastatic melanoma (ECHO-301/KEYNOTE-252): a phase 3, randomised, double-blind study. Lancet Oncol. 2019 08; 20(8):1083-1097. PMID: 31221619.
      Citations: 380     Fields:    Translation:HumansCTClinical Trials
    51. Fessler J, Matson V, Gajewski TF. Exploring the emerging role of the microbiome in cancer immunotherapy. J Immunother Cancer. 2019 04 17; 7(1):108. PMID: 30995949; PMCID: PMC6471869.
      Citations: 118     Fields:    Translation:HumansAnimals
    52. Stein JE, Soni A, Danilova L, Cottrell TR, Gajewski TF, Hodi FS, Bhatia S, Urba WJ, Sharfman WH, Wind-Rotolo M, Edwards R, Lipson EJ, Taube JM. Major pathologic response on biopsy (MPRbx) in patients with advanced melanoma treated with anti-PD-1: evidence for an early, on-therapy biomarker of response. Ann Oncol. 2019 04 01; 30(4):589-596. PMID: 30689736; PMCID: PMC6503625.
      Citations: 20     Fields:    Translation:HumansCTClinical Trials
    53. Gibney GT, Hamid O, Lutzky J, Olszanski AJ, Mitchell TC, Gajewski TF, Chmielowski B, Hanks BA, Zhao Y, Newton RC, Maleski J, Leopold L, Weber JS. Phase 1/2 study of epacadostat in combination with ipilimumab in patients with unresectable or metastatic melanoma. J Immunother Cancer. 2019 03 20; 7(1):80. PMID: 30894212; PMCID: PMC6425606.
      Citations: 38     Fields:    Translation:HumansCTClinical Trials
    54. Tomaszewski W, Sanchez-Perez L, Gajewski TF, Sampson JH. Brain Tumor Microenvironment and Host State: Implications for Immunotherapy. Clin Cancer Res. 2019 07 15; 25(14):4202-4210. PMID: 30804019; PMCID: PMC6635001.
      Citations: 145     Fields:    Translation:HumansAnimalsCells
    55. Luke JJ, Bao R, Sweis RF, Spranger S, Gajewski TF. WNT/ß-catenin Pathway Activation Correlates with Immune Exclusion across Human Cancers. Clin Cancer Res. 2019 May 15; 25(10):3074-3083. PMID: 30635339; PMCID: PMC6522301.
      Citations: 286     Fields:    Translation:HumansCells
    56. Blaha DT, Anderson SD, Yoakum DM, Hager MV, Zha Y, Gajewski TF, Kranz DM. High-Throughput Stability Screening of Neoantigen/HLA Complexes Improves Immunogenicity Predictions. Cancer Immunol Res. 2019 01; 7(1):50-61. PMID: 30425106; PMCID: PMC6324732.
      Citations: 18     Fields:    
    57. Mitchell TC, Hamid O, Smith DC, Bauer TM, Wasser JS, Olszanski AJ, Luke JJ, Balmanoukian AS, Schmidt EV, Zhao Y, Gong X, Maleski J, Leopold L, Gajewski TF. Epacadostat Plus Pembrolizumab in Patients With Advanced Solid Tumors: Phase I Results From a Multicenter, Open-Label Phase I/II Trial (ECHO-202/KEYNOTE-037). J Clin Oncol. 2018 Nov 10; 36(32):3223-3230. PMID: 30265610; PMCID: PMC6225502.
      Citations: 185     Fields:    
    58. Miller ML, McIntosh CM, Williams JB, Wang Y, Hollinger MK, Isaad NJ, Moon JJ, Gajewski TF, Chong AS, Alegre ML. Distinct Graft-Specific TCR Avidity Profiles during Acute Rejection and Tolerance. Cell Rep. 2018 08 21; 24(8):2112-2126. PMID: 30134172; PMCID: PMC6142813.
      Citations: 15     Fields:    Translation:HumansAnimals
    59. Ishihara J, Ishihara A, Potin L, Hosseinchi P, Fukunaga K, Damo M, Gajewski TF, Swartz MA, Hubbell JA. Improving Efficacy and Safety of Agonistic Anti-CD40 Antibody Through Extracellular Matrix Affinity. Mol Cancer Ther. 2018 11; 17(11):2399-2411. PMID: 30097487.
      Citations: 21     Fields:    Translation:HumansAnimalsCells
    60. Ribas A, Dummer R, Puzanov I, VanderWalde A, Andtbacka RHI, Michielin O, Olszanski AJ, Malvehy J, Cebon J, Fernandez E, Kirkwood JM, Gajewski TF, Chen L, Gorski KS, Anderson AA, Diede SJ, Lassman ME, Gansert J, Hodi FS, Long GV. Oncolytic Virotherapy Promotes Intratumoral T Cell Infiltration and Improves Anti-PD-1 Immunotherapy. Cell. 2018 08 09; 174(4):1031-1032. PMID: 30096300.
      Citations: 74     Fields:    
    61. Ascierto PA, Puzanov I, Agarwala SS, Bifulco C, Botti G, Ciliberto G, Davies MA, Dummer R, Ferrone S, Gajewski TF, Garbe C, Luke JJ, Marincola FM, Masucci G, Mehnert JM, Mozzillo N, Palmieri G, Postow MA, Schoenberger SP, Wang E, Thurin M, Caracò C. Perspectives in melanoma: Meeting report from the Melanoma Bridge (30 November-2 December, 2017, Naples, Italy). J Transl Med. 2018 07 21; 16(1):207. PMID: 30031393; PMCID: PMC6054754.
      Citations: 3     Fields:    Translation:Humans
    62. Hantel A, Gabster B, Cheng JX, Golomb H, Gajewski TF. Severe hemophagocytic lymphohistiocytosis in a melanoma patient treated with ipilimumab + nivolumab. J Immunother Cancer. 2018 07 16; 6(1):73. PMID: 30012206; PMCID: PMC6048909.
      Citations: 25     Fields:    Translation:Humans
    63. Sehdev A, Karrison T, Zha Y, Janisch L, Turcich M, Cohen EEW, Maitland M, Polite BN, Gajewski TF, Salgia R, Pinto N, Bissonnette MB, Fleming GF, Ratain MJ, Sharma MR. A pharmacodynamic study of sirolimus and metformin in patients with advanced solid tumors. Cancer Chemother Pharmacol. 2018 08; 82(2):309-317. PMID: 29948021; PMCID: PMC6739841.
      Citations: 9     Fields:    Translation:HumansCells
    64. Sullivan RJ, Atkins MB, Kirkwood JM, Agarwala SS, Clark JI, Ernstoff MS, Fecher L, Gajewski TF, Gastman B, Lawson DH, Lutzky J, McDermott DF, Margolin KA, Mehnert JM, Pavlick AC, Richards JM, Rubin KM, Sharfman W, Silverstein S, Slingluff CL, Sondak VK, Tarhini AA, Thompson JA, Urba WJ, White RL, Whitman ED, Hodi FS, Kaufman HL. An update on the Society for Immunotherapy of Cancer consensus statement on tumor immunotherapy for the treatment of cutaneous melanoma: version 2.0. J Immunother Cancer. 2018 05 30; 6(1):44. PMID: 29848375; PMCID: PMC5977556.
      Citations: 32     Fields:    Translation:Humans
    65. Gajewski TF. Fast Forward - Neoadjuvant Cancer Immunotherapy. N Engl J Med. 2018 05 24; 378(21):2034-2035. PMID: 29791816.
      Citations: 4     Fields:    Translation:Humans
    66. Sweis RF, Zha Y, Pass L, Heiss B, Chongsuwat T, Luke JJ, Gajewski TF, Szmulewitz R. Pseudoprogression manifesting as recurrent ascites with anti-PD-1 immunotherapy in urothelial bladder cancer. J Immunother Cancer. 2018 04 04; 6(1):24. PMID: 29618376; PMCID: PMC5883337.
      Citations: 7     Fields:    Translation:HumansCells
    67. Ma Y, Gajewski TF, Zitvogel L, Raoult D, Kroemer G. The microbiome in cancer immunotherapy: Diagnostic tools and therapeutic strategies. Science. 2018 03 23; 359(6382):1366-1370. PMID: 29567708.
      Citations: 280     Fields:    Translation:Humans
    68. Luke JJ, Lemons JM, Karrison TG, Pitroda SP, Melotek JM, Zha Y, Al-Hallaq HA, Arina A, Khodarev NN, Janisch L, Chang P, Patel JD, Fleming GF, Moroney J, Sharma MR, White JR, Ratain MJ, Gajewski TF, Weichselbaum RR, Chmura SJ. Safety and Clinical Activity of Pembrolizumab and Multisite Stereotactic Body Radiotherapy in Patients With Advanced Solid Tumors. J Clin Oncol. 2018 06 01; 36(16):1611-1618. PMID: 29437535; PMCID: PMC5978468.
      Citations: 253     Fields:    Translation:HumansCTClinical Trials
    69. Horton BL, Gajewski TF. Back from the dead: TIL apoptosis in cancer immune evasion. Br J Cancer. 2018 02 06; 118(3):309-311. PMID: 29360810; PMCID: PMC5808044.
      Citations: 4     Fields:    Translation:HumansCells
    70. Spranger S, Gajewski TF. Impact of oncogenic pathways on evasion of antitumour immune responses. Nat Rev Cancer. 2018 03; 18(3):139-147. PMID: 29326431; PMCID: PMC6685071.
      Citations: 297     Fields:    Translation:HumansCells
    71. Liu H, Zha Y, Choudhury N, Malnassy G, Fulton N, Green M, Park JH, Nakamura Y, Larson RA, Salazar AM, Odenike O, Gajewski TF, Stock W. WT1 peptide vaccine in Montanide in contrast to poly ICLC, is able to induce WT1-specific immune response with TCR clonal enrichment in myeloid leukemia. Exp Hematol Oncol. 2018; 7:1. PMID: 29344432; PMCID: PMC5765712.
      Citations: 11     
    72. Matson V, Fessler J, Bao R, Chongsuwat T, Zha Y, Alegre ML, Luke JJ, Gajewski TF. The commensal microbiome is associated with anti-PD-1 efficacy in metastatic melanoma patients. Science. 2018 01 05; 359(6371):104-108. PMID: 29302014; PMCID: PMC6707353.
      Citations: 1155     Fields:    Translation:HumansAnimalsCells
    73. Horton BL, Williams JB, Cabanov A, Spranger S, Gajewski TF. Intratumoral CD8+ T-cell Apoptosis Is a Major Component of T-cell Dysfunction and Impedes Antitumor Immunity. Cancer Immunol Res. 2018 01; 6(1):14-24. PMID: 29097422; PMCID: PMC5754226.
      Citations: 89     Fields:    Translation:HumansAnimalsCells
    74. Riaz N, Havel JJ, Makarov V, Desrichard A, Urba WJ, Sims JS, Hodi FS, Mandal R, Sharfman WH, Bhatia S, Hwu WJ, Gajewski TF, Slingluff CL, Chowell D, Kendall SM, Chang H, Shah R, Kuo F, Morris LGT, Sidhom JW, Schneck JP, Horak CE, Weinhold N, Chan TA, Martín-Algarra S. Tumor and Microenvironment Evolution during Immunotherapy with Nivolumab. Cell. 2017 Nov 02; 171(4):934-949.e16. PMID: 29033130; PMCID: PMC5685550.
      Citations: 914     Fields:    Translation:HumansCells
    75. Ribas A, Dummer R, Puzanov I, VanderWalde A, Andtbacka RHI, Michielin O, Olszanski AJ, Malvehy J, Cebon J, Kirkwood JM, Gajewski TF, Chen L, Gorski KS, Anderson AA, Diede SJ, Lassman ME, Gansert J, Hodi FS, Long GV, Fernandez E. Oncolytic Virotherapy Promotes Intratumoral T Cell Infiltration and Improves Anti-PD-1 Immunotherapy. Cell. 2017 Sep 07; 170(6):1109-1119.e10. PMID: 28886381; PMCID: PMC8034392.
      Citations: 666     Fields:    Translation:HumansCellsCTClinical Trials
    76. Tarhini AA, Moschos SJ, Lin Y, Lin HM, Sander C, Yin Y, Venhaus R, Gajewski TF, Kirkwood JM. Safety and efficacy of the antiganglioside GD3 antibody ecromeximab (KW2871) combined with high-dose interferon-a2b in patients with metastatic melanoma. Melanoma Res. 2017 08; 27(4):342-350. PMID: 28489678.
      Citations: 11     Fields:    Translation:HumansCTClinical Trials
    77. Spranger S, Dai D, Horton B, Gajewski TF. Tumor-Residing Batf3 Dendritic Cells Are Required for Effector T Cell Trafficking and Adoptive T Cell Therapy. Cancer Cell. 2017 05 08; 31(5):711-723.e4. PMID: 28486109; PMCID: PMC5650691.
      Citations: 621     Fields:    Translation:AnimalsCells
    78. Fessler JL, Gajewski TF. The Microbiota: A New Variable Impacting Cancer Treatment Outcomes. Clin Cancer Res. 2017 07 01; 23(13):3229-3231. PMID: 28446507; PMCID: PMC5627769.
      Citations: 11     Fields:    Translation:Humans
    79. Williams JB, Horton BL, Zheng Y, Duan Y, Powell JD, Gajewski TF. The EGR2 targets LAG-3 and 4-1BB describe and regulate dysfunctional antigen-specific CD8+ T cells in the tumor microenvironment. J Exp Med. 2017 02; 214(2):381-400. PMID: 28115575; PMCID: PMC5294847.
      Citations: 88     Fields:    Translation:AnimalsCells
    80. Beatty GL, O'Dwyer PJ, Clark J, Shi JG, Bowman KJ, Scherle PA, Newton RC, Schaub R, Maleski J, Leopold L, Gajewski TF. First-in-Human Phase I Study of the Oral Inhibitor of Indoleamine 2,3-Dioxygenase-1 Epacadostat (INCB024360) in Patients with Advanced Solid Malignancies. Clin Cancer Res. 2017 07 01; 23(13):3269-3276. PMID: 28053021; PMCID: PMC5496788.
      Citations: 141     Fields:    Translation:HumansCTClinical Trials
    81. Gajewski TF, Corrales L, Williams J, Horton B, Sivan A, Spranger S. Cancer Immunotherapy Targets Based on Understanding the T Cell-Inflamed Versus Non-T Cell-Inflamed Tumor Microenvironment. Adv Exp Med Biol. 2017; 1036:19-31. PMID: 29275462; PMCID: PMC6693322.
      Citations: 142     Fields:    Translation:HumansAnimalsCells
    82. Mateo F, Arenas EJ, Aguilar H, Serra-Musach J, de Garibay GR, Boni J, Maicas M, Du S, Iorio F, Herranz-Ors C, Islam A, Prado X, Llorente A, Petit A, Vidal A, Soler T, Venturas G, Rojo-Sebastian A, Serra H, Cuadras D, Blanco I, Canals F, Sieuwerts AM, de Weerd V, Look MP, Puertas S, Perkins AS, Bonifaci N, Skowron M, Serrat X, Brunet J, Barretina MP, Gil M, Falo C, Morilla I, Pernas S, Ballester R, Nellist M, Morales S, Valls J, Velasco A, Matias-Guiu X, Figueras A, Cordero A, Palomero L, Gajewski TF, Cohen EEW, Jesiotr M, Bodnar L, Quintela-Fandino M, Puente XS, Casanovas O, Graupera M, Saez-Rodriguez J, Esteller M, Sierra A, Matheu A, Carracedo A, Nanjundan M, Odero MD, Martens JWM, Moreno-Bueno G, Barcellos-Hoff MH, Villanueva A, Gomis RR, Pujana MA, Català I, Lozano J, García N, Gómez-Baldó L, Hernández V, Martínez-Aranda A, Martínez-Iniesta M, Cerón J, Fernández A, Plà MJ, Andreu X, Seguí MA, Castellà E, Sánchez-Mut JV, Sánchez-Céspedes M, Gómez-Miragaya J, Gómez A, López-Bigas N, Valdés-Mas R, Viñals F, Hernández-Losa J, Ramón Y Cajal S, García-Alonso L, Martín-Martín N, González-Suárez E, Cortés J, Lázaro C. Stem cell-like transcriptional reprogramming mediates metastatic resistance to mTOR inhibition. Oncogene. 2017 05 11; 36(19):2737-2749. PMID: 27991928; PMCID: PMC5442428.
      Citations: 16     Fields:    Translation:HumansCells
    83. Corrales L, Matson V, Flood B, Spranger S, Gajewski TF. Innate immune signaling and regulation in cancer immunotherapy. Cell Res. 2017 Jan; 27(1):96-108. PMID: 27981969; PMCID: PMC5223230.
      Citations: 175     Fields:    Translation:HumansCells
    84. Atkinson TM, Hay JL, Shoushtari A, Li Y, Paucar DJ, Smith SC, Kudchadkar RR, Doyle A, Sosman JA, Quevedo JF, Milhem MM, Joshua AM, Linette GP, Gajewski TF, Lutzky J, Lawson DH, Lao CD, Flynn PJ, Albertini MR, Sato T, Lewis K, Marr B, Abramson DH, Dickson MA, Schwartz GK, Carvajal RD. Relationship between physician-adjudicated adverse events and patient-reported health-related quality of life in a phase II clinical trial (NCT01143402) of patients with metastatic uveal melanoma. J Cancer Res Clin Oncol. 2017 Mar; 143(3):439-445. PMID: 27921276; PMCID: PMC5303646.
      Citations:    Fields:    Translation:HumansCTClinical Trials
    85. Bauman JE, Cohen E, Ferris RL, Adelstein DJ, Brizel DM, Ridge JA, O'Sullivan B, Burtness BA, Butterfield LH, Carson WE, Disis ML, Fox BA, Gajewski TF, Gillison ML, Hodge JW, Le QT, Raben D, Strome SE, Lynn J, Malik S. Immunotherapy of head and neck cancer: Emerging clinical trials from a National Cancer Institute Head and Neck Cancer Steering Committee Planning Meeting. Cancer. 2017 Apr 01; 123(7):1259-1271. PMID: 27906454; PMCID: PMC5705038.
      Citations: 25     Fields:    Translation:Humans
    86. Ascierto PA, Agarwala S, Botti G, Cesano A, Ciliberto G, Davies MA, Demaria S, Eggermont AM, Ferrone S, Fu YX, Gajewski TF, Huber V, Khleif S, Krauthammer M, Lo RS, Masucci G, Palmieri G, Postow M, Puzanov I, Silk A, Spranger S, Stroncek DF, Tarhini A, Taube JM, Testori A, Wang E, Wargo JA, Yee C, Zarour H, Zitvogel L, Fox BA, Mozzillo N, Marincola FM, Thurin M, Dummer R, Garbe C. Future perspectives in melanoma research : Meeting report from the "Melanoma Bridge". Napoli, December 1st-4th 2015. J Transl Med. 2016 11 15; 14(1):313. PMID: 27846884; PMCID: PMC5111349.
      Citations: 6     Fields:    Translation:HumansAnimals
    87. Spranger S, Luke JJ, Bao R, Zha Y, Hernandez KM, Li Y, Gajewski AP, Andrade J, Gajewski TF. Density of immunogenic antigens does not explain the presence or absence of the T-cell-inflamed tumor microenvironment in melanoma. Proc Natl Acad Sci U S A. 2016 11 29; 113(48):E7759-E7768. PMID: 27837020; PMCID: PMC5137753.
      Citations: 197     Fields:    Translation:HumansCells
    88. Salerno EP, Bedognetti D, Mauldin IS, Deacon DH, Shea SM, Pinczewski J, Obeid JM, Coukos G, Wang E, Gajewski TF, Marincola FM, Slingluff CL. Human melanomas and ovarian cancers overexpressing mechanical barrier molecule genes lack immune signatures and have increased patient mortality risk. Oncoimmunology. 2016; 5(12):e1240857. PMID: 28123876; PMCID: PMC5215363.
      Citations: 40     Fields:    
    89. Heinzerling L, Ott PA, Hodi FS, Husain AN, Tajmir-Riahi A, Tawbi H, Gajewski TF, Lipson EJ, Luke JJ, Pauschinger M. Cardiotoxicity associated with CTLA4 and PD1 blocking immunotherapy. J Immunother Cancer. 2016; 4:50. PMID: 27532025; PMCID: PMC4986340.
      Citations: 219     Fields:    
    90. Lund AW, Wagner M, Fankhauser M, Steinskog ES, Broggi MA, Spranger S, Gajewski TF, Alitalo K, Eikesdal HP, Wiig H, Swartz MA. Lymphatic vessels regulate immune microenvironments in human and murine melanoma. J Clin Invest. 2016 09 01; 126(9):3389-402. PMID: 27525437; PMCID: PMC5004967.
      Citations: 110     Fields:    Translation:HumansAnimals
    91. Corrales L, McWhirter SM, Dubensky TW, Gajewski TF. The host STING pathway at the interface of cancer and immunity. J Clin Invest. 2016 07 01; 126(7):2404-11. PMID: 27367184; PMCID: PMC4922692.
      Citations: 200     Fields:    Translation:HumansAnimalsCells
    92. Gajewski TF, Iraolagoitia XL, Spallanzani RG, Torres NI, Araya RE, Ziblat A, Domaica CI, Sierra JM, Nuñez SY, Secchiari F, Zwirner NW, Fuertes MB. NK Cells Restrain Spontaneous Antitumor CD8+ T Cell Priming through PD-1/PD-L1 Interactions with Dendritic Cells. J Immunol. 2016 08 01; 197(3):953-61. PMID: 27342842.
      Citations: 56     Fields:    Translation:HumansAnimalsCells
    93. Luke JJ, Zha Y, Matijevich K, Gajewski TF. Single dose denileukin diftitox does not enhance vaccine-induced T cell responses or effectively deplete Tregs in advanced melanoma: immune monitoring and clinical results of a randomized phase II trial. J Immunother Cancer. 2016; 4:35. PMID: 27330808; PMCID: PMC4915048.
      Citations: 10     Fields:    
    94. Lei YM, Chen L, Wang Y, Stefka AT, Molinero LL, Theriault B, Aquino-Michaels K, Sivan AS, Nagler CR, Gajewski TF, Chong AS, Bartman C, Alegre ML. The composition of the microbiota modulates allograft rejection. J Clin Invest. 2016 07 01; 126(7):2736-44. PMID: 27322054; PMCID: PMC4922695.
      Citations: 42     Fields:    Translation:AnimalsCells
    95. Gajewski T. Manipulating the microbiome to improve the efficacy of immunotherapy. Clin Adv Hematol Oncol. 2016 Jun; 14(6):424-6. PMID: 27379811.
      Citations: 4     Fields:    Translation:HumansCells
    96. Sweis RF, Spranger S, Bao R, Paner GP, Stadler WM, Steinberg G, Gajewski TF. Molecular Drivers of the Non-T-cell-Inflamed Tumor Microenvironment in Urothelial Bladder Cancer. Cancer Immunol Res. 2016 07; 4(7):563-8. PMID: 27197067; PMCID: PMC4943758.
      Citations: 184     Fields:    Translation:HumansCells
    97. Spranger S, Gajewski TF, Kline J. MYC - a thorn in the side of cancer immunity. Cell Res. 2016 06; 26(6):639-40. PMID: 27113275; PMCID: PMC4897180.
      Citations: 5     Fields:    Translation:Humans
    98. Alegre ML, Gajewski TF. Germ Warfare. Sci Am. 2016 Apr; 314(4):50. PMID: 27082192.
      Citations:    Fields:    Translation:HumansAnimalsCells
    99. Corrales L, Woo SR, Williams JB, McWhirter SM, Dubensky TW, Gajewski TF. Antagonism of the STING Pathway via Activation of the AIM2 Inflammasome by Intracellular DNA. J Immunol. 2016 Apr 01; 196(7):3191-8. PMID: 26927800; PMCID: PMC4800192.
      Citations: 65     Fields:    Translation:AnimalsCells
    100. Spranger S, Barnes SE, Miller ML, Molinero LL, Locke FL, Gajewski TF, Alegre ML, Evaristo C. Cutting Edge: Engineering Active IKKß in T Cells Drives Tumor Rejection. J Immunol. 2016 Apr 01; 196(7):2933-8. PMID: 26903482; PMCID: PMC4799771.
      Citations: 14     Fields:    Translation:HumansAnimalsCells
    101. Mikucki ME, Skitzki JJ, Frelinger JG, Odunsi K, Gajewski TF, Luster AD, Evans SS. Unlocking tumor vascular barriers with CXCR3: Implications for cancer immunotherapy. Oncoimmunology. 2016 May; 5(5):e1116675. PMID: 27467928; PMCID: PMC4910745.
      Citations: 7     Fields:    
    102. McWhirter E, Quirt I, Gajewski T, Pond G, Wang L, Hui J, Oza A. A phase II study of cediranib, an oral VEGF inhibitor, in previously untreated patients with metastatic or recurrent malignant melanoma. Invest New Drugs. 2016 Apr; 34(2):231-5. PMID: 26841902.
      Citations: 4     Fields:    Translation:HumansCTClinical Trials
    103. Spranger S, Sivan A, Corrales L, Gajewski TF. Tumor and Host Factors Controlling Antitumor Immunity and Efficacy of Cancer Immunotherapy. Adv Immunol. 2016; 130:75-93. PMID: 26923000; PMCID: PMC4864964.
      Citations: 49     Fields:    Translation:HumansAnimalsCells
    104. Peng W, Chen JQ, Liu C, Malu S, Creasy C, Tetzlaff MT, Xu C, McKenzie JA, Zhang C, Liang X, Williams LJ, Deng W, Chen G, Mbofung R, Lazar AJ, Torres-Cabala CA, Cooper ZA, Chen PL, Tieu TN, Spranger S, Yu X, Bernatchez C, Forget MA, Haymaker C, Amaria R, McQuade JL, Glitza IC, Cascone T, Li HS, Kwong LN, Heffernan TP, Hu J, Bassett RL, Bosenberg MW, Woodman SE, Overwijk WW, Roszik J, Gajewski TF, Wargo JA, Gershenwald JE, Radvanyi L, Davies MA, Hwu P, Lizée G. Loss of PTEN Promotes Resistance to T Cell-Mediated Immunotherapy. Cancer Discov. 2016 Feb; 6(2):202-16. PMID: 26645196; PMCID: PMC4744499.
      Citations: 741     Fields:    Translation:HumansAnimalsCells
    105. Ascierto PA, Atkins M, Bifulco C, Botti G, Cochran A, Davies M, Demaria S, Ferrone S, Formenti S, Gajewski TF, Khleif S, Kiessling R, Lo R, Lorigan P, Arthur GM, Masucci G, Mihm M, Palmieri G, Parmiani G, Puzanov I, Romero P, Schilling B, Seliger B, Stroncek D, Taube J, Tomei S, Zarour HM, Testori A, Wang E, Ciliberto G, Mozzillo N, Marincola FM, Thurin M, Dummer R, Garbe C, Melero I, Galon J. Future perspectives in melanoma research: meeting report from the "Melanoma Bridge": Napoli, December 3rd-6th 2014. J Transl Med. 2015 Nov 30; 13:374. PMID: 26619946; PMCID: PMC4665874.
      Citations: 6     Fields:    Translation:Humans
    106. Sivan A, Corrales L, Hubert N, Williams JB, Aquino-Michaels K, Earley ZM, Benyamin FW, Lei YM, Jabri B, Alegre ML, Chang EB, Gajewski TF. Commensal Bifidobacterium promotes antitumor immunity and facilitates anti-PD-L1 efficacy. Science. 2015 Nov 27; 350(6264):1084-9. PMID: 26541606; PMCID: PMC4873287.
      Citations: 1538     Fields:    Translation:HumansAnimalsCells
    107. Spranger S, Gajewski TF. A new paradigm for tumor immune escape: ß-catenin-driven immune exclusion. J Immunother Cancer. 2015; 3:43. PMID: 26380088; PMCID: PMC4570721.
      Citations: 71     Fields:    
    108. Corrales L, Gajewski TF. Molecular Pathways: Targeting the Stimulator of Interferon Genes (STING) in the Immunotherapy of Cancer. Clin Cancer Res. 2015 Nov 01; 21(21):4774-9. PMID: 26373573; PMCID: PMC4750108.
      Citations: 83     Fields:    Translation:HumansAnimalsCells
    109. Spranger S, Gajewski TF. Tumor-intrinsic oncogene pathways mediating immune avoidance. Oncoimmunology. 2016 Mar; 5(3):e1086862. PMID: 27141343; PMCID: PMC4839364.
      Citations: 81     Fields:    
    110. Corrales L, Gajewski TF. Endogenous and pharmacologic targeting of the STING pathway in cancer immunotherapy. Cytokine. 2016 Jan; 77:245-7. PMID: 26315534; PMCID: PMC4666728.
      Citations: 21     Fields:    Translation:HumansCells
    111. Mikucki ME, Fisher DT, Matsuzaki J, Skitzki JJ, Gaulin NB, Muhitch JB, Ku AW, Frelinger JG, Odunsi K, Gajewski TF, Luster AD, Evans SS. Non-redundant requirement for CXCR3 signalling during tumoricidal T-cell trafficking across tumour vascular checkpoints. Nat Commun. 2015 Jun 25; 6:7458. PMID: 26109379; PMCID: PMC4605273.
      Citations: 246     Fields:    Translation:AnimalsCells
    112. Gajewski TF. The Next Hurdle in Cancer Immunotherapy: Overcoming the Non-T-Cell-Inflamed Tumor Microenvironment. Semin Oncol. 2015 Aug; 42(4):663-71. PMID: 26320069; PMCID: PMC4555998.
      Citations: 249     Fields:    Translation:HumansAnimalsCells
    113. Spranger S, Bao R, Gajewski TF. Melanoma-intrinsic ß-catenin signalling prevents anti-tumour immunity. Nature. 2015 Jul 09; 523(7559):231-5. PMID: 25970248.
      Citations: 1340     Fields:    Translation:HumansAnimalsCells
    114. Corrales L, Glickman LH, McWhirter SM, Kanne DB, Sivick KE, Katibah GE, Woo SR, Lemmens E, Banda T, Leong JJ, Metchette K, Dubensky TW, Gajewski TF. Direct Activation of STING in the Tumor Microenvironment Leads to Potent and Systemic Tumor Regression and Immunity. Cell Rep. 2015 May 19; 11(7):1018-30. PMID: 25959818; PMCID: PMC4440852.
      Citations: 612     Fields:    Translation:HumansAnimalsCells
    115. Woo SR, Corrales L, Gajewski TF. The STING pathway and the T cell-inflamed tumor microenvironment. Trends Immunol. 2015 Apr; 36(4):250-6. PMID: 25758021; PMCID: PMC4393801.
      Citations: 112     Fields:    Translation:HumansCells
    116. Carvajal RD, Lawrence DP, Weber JS, Gajewski TF, Gonzalez R, Lutzky J, O'Day SJ, Hamid O, Wolchok JD, Chapman PB, Sullivan RJ, Teitcher JB, Ramaiya N, Giobbie-Hurder A, Antonescu CR, Heinrich MC, Bastian BC, Corless CL, Fletcher JA, Hodi FS. Phase II Study of Nilotinib in Melanoma Harboring KIT Alterations Following Progression to Prior KIT Inhibition. Clin Cancer Res. 2015 May 15; 21(10):2289-96. PMID: 25695690; PMCID: PMC5013827.
      Citations: 50     Fields:    Translation:HumansCTClinical Trials
    117. Woo SR, Corrales L, Gajewski TF. Innate immune recognition of cancer. Annu Rev Immunol. 2015; 33:445-74. PMID: 25622193.
      Citations: 259     Fields:    Translation:HumansAnimalsCells
    118. Barnes SE, Wang Y, Chen L, Molinero LL, Gajewski TF, Evaristo C, Alegre ML. T cell-NF-?B activation is required for tumor control in vivo. J Immunother Cancer. 2015; 3(1):1. PMID: 25648675; PMCID: PMC4308877.
      Citations: 24     Fields:    
    119. Gajewski TF, Corrales L. New perspectives on type I IFNs in cancer. Cytokine Growth Factor Rev. 2015 Apr; 26(2):175-8. PMID: 25630967; PMCID: PMC4387009.
      Citations: 29     Fields:    Translation:HumansAnimalsCells
    120. Janardhan SV, Marks R, Gajewski TF. Primary murine CD4+ T cells fail to acquire the ability to produce effector cytokines when active Ras is present during Th1/Th2 differentiation. PLoS One. 2014; 9(11):e112831. PMID: 25397617; PMCID: PMC4232516.
      Citations: 1     Fields:    Translation:AnimalsCells
    121. Zukotynski K, Yap JT, Giobbie-Hurder A, Weber J, Gonzalez R, Gajewski TF, O'Day S, Kim K, Hodi FS, Van den Abbeele AD. Metabolic response by FDG-PET to imatinib correlates with exon 11 KIT mutation and predicts outcome in patients with mucosal melanoma. Cancer Imaging. 2014 Nov 12; 14:30. PMID: 25609545; PMCID: PMC4331835.
      Citations: 6     Fields:    Translation:HumansCTClinical Trials
    122. Deng L, Liang H, Xu M, Yang X, Burnette B, Arina A, Li XD, Mauceri H, Beckett M, Darga T, Huang X, Gajewski TF, Chen ZJ, Fu YX, Weichselbaum RR. STING-Dependent Cytosolic DNA Sensing Promotes Radiation-Induced Type I Interferon-Dependent Antitumor Immunity in Immunogenic Tumors. Immunity. 2014 Nov 20; 41(5):843-52. PMID: 25517616; PMCID: PMC5155593.
      Citations: 859     Fields:    Translation:AnimalsCells
    123. Woo SR, Fuertes MB, Corrales L, Spranger S, Furdyna MJ, Leung MY, Duggan R, Wang Y, Fitzgerald KA, Alegre ML, Gajewski TF, Barber GN. STING-dependent cytosolic DNA sensing mediates innate immune recognition of immunogenic tumors. Immunity. 2014 Nov 20; 41(5):830-42. PMID: 25517615; PMCID: PMC4384884.
      Citations: 734     Fields:    Translation:AnimalsCells
    124. Ascierto PA, Grimaldi AM, Anderson AC, Bifulco C, Cochran A, Garbe C, Eggermont AM, Faries M, Ferrone S, Gershenwald JE, Gajewski TF, Halaban R, Hodi FS, Kefford R, Kirkwood JM, Larkin J, Leachman S, Maio M, Marais R, Masucci G, Melero I, Palmieri G, Puzanov I, Ribas A, Saenger Y, Schilling B, Seliger B, Stroncek D, Sullivan R, Testori A, Wang E, Ciliberto G, Mozzillo N, Marincola FM, Thurin M. Future perspectives in melanoma research: meeting report from the "Melanoma Bridge", Napoli, December 5th-8th 2013. J Transl Med. 2014 Oct 28; 12:277. PMID: 25348889; PMCID: PMC4232645.
      Citations: 10     Fields:    Translation:Humans
    125. Lee SM, Moon J, Redman BG, Chidiac T, Flaherty LE, Zha Y, Othus M, Ribas A, Sondak VK, Gajewski TF, Margolin KA. Phase 2 study of RO4929097, a gamma-secretase inhibitor, in metastatic melanoma: SWOG 0933. Cancer. 2015 Feb 01; 121(3):432-440. PMID: 25250858; PMCID: PMC4304973.
      Citations: 48     Fields:    Translation:HumansCellsCTClinical Trials
    126. Spaapen RM, Leung MY, Fuertes MB, Kline JP, Zhang L, Zheng Y, Fu YX, Luo X, Cohen KS, Gajewski TF. Therapeutic activity of high-dose intratumoral IFN-ß requires direct effect on the tumor vasculature. J Immunol. 2014 Oct 15; 193(8):4254-60. PMID: 25217157.
      Citations: 50     Fields:    Translation:AnimalsCells
    127. Ribas A, Gonzalez R, Pavlick A, Hamid O, Gajewski TF, Daud A, Flaherty L, Logan T, Chmielowski B, Lewis K, Kee D, Boasberg P, Yin M, Chan I, Musib L, Choong N, Puzanov I, McArthur GA. Combination of vemurafenib and cobimetinib in patients with advanced BRAF(V600)-mutated melanoma: a phase 1b study. Lancet Oncol. 2014 Aug; 15(9):954-65. PMID: 25037139.
      Citations: 94     Fields:    Translation:HumansCTClinical Trials
    128. Carvajal RD, Sosman JA, Quevedo JF, Milhem MM, Joshua AM, Kudchadkar RR, Linette GP, Gajewski TF, Lutzky J, Lawson DH, Lao CD, Flynn PJ, Albertini MR, Sato T, Lewis K, Doyle A, Ancell K, Panageas KS, Bluth M, Hedvat C, Erinjeri J, Ambrosini G, Marr B, Abramson DH, Dickson MA, Wolchok JD, Chapman PB, Schwartz GK. Effect of selumetinib vs chemotherapy on progression-free survival in uveal melanoma: a randomized clinical trial. JAMA. 2014 Jun 18; 311(23):2397-405. PMID: 24938562; PMCID: PMC4249701.
      Citations: 184     Fields:    Translation:HumansCTClinical Trials
    129. Spranger S, Koblish HK, Horton B, Scherle PA, Newton R, Gajewski TF. Mechanism of tumor rejection with doublets of CTLA-4, PD-1/PD-L1, or IDO blockade involves restored IL-2 production and proliferation of CD8(+) T cells directly within the tumor microenvironment. J Immunother Cancer. 2014; 2:3. PMID: 24829760; PMCID: PMC4019906.
      Citations: 298     Fields:    
    130. Yang X, Zhang X, Fu ML, Weichselbaum RR, Gajewski TF, Guo Y, Fu YX. Targeting the tumor microenvironment with interferon-ß bridges innate and adaptive immune responses. Cancer Cell. 2014 Jan 13; 25(1):37-48. PMID: 24434209; PMCID: PMC3927846.
      Citations: 144     Fields:    Translation:AnimalsCells
    131. Gajewski TF, Schreiber H, Fu YX. Innate and adaptive immune cells in the tumor microenvironment. Nat Immunol. 2013 Oct; 14(10):1014-22. PMID: 24048123; PMCID: PMC4118725.
      Citations: 1829     Fields:    Translation:HumansAnimalsCells
    132. Spranger S, Gajewski T. Rational combinations of immunotherapeutics that target discrete pathways. J Immunother Cancer. 2013; 1:16. PMID: 24829752; PMCID: PMC4019905.
      Citations: 34     Fields:    
    133. Spranger S, Spaapen RM, Zha Y, Williams J, Meng Y, Ha TT, Gajewski TF. Up-regulation of PD-L1, IDO, and T(regs) in the melanoma tumor microenvironment is driven by CD8(+) T cells. Sci Transl Med. 2013 Aug 28; 5(200):200ra116. PMID: 23986400; PMCID: PMC4136707.
      Citations: 845     Fields:    Translation:HumansAnimalsCells
    134. Kaufman HL, Kirkwood JM, Hodi FS, Agarwala S, Amatruda T, Bines SD, Clark JI, Curti B, Ernstoff MS, Gajewski T, Gonzalez R, Hyde LJ, Lawson D, Lotze M, Lutzky J, Margolin K, McDermott DF, Morton D, Pavlick A, Richards JM, Sharfman W, Sondak VK, Sosman J, Steel S, Tarhini A, Thompson JA, Titze J, Urba W, White R, Atkins MB. The Society for Immunotherapy of Cancer consensus statement on tumour immunotherapy for the treatment of cutaneous melanoma. Nat Rev Clin Oncol. 2013 10; 10(10):588-98. PMID: 23982524.
      Citations: 85     Fields:    Translation:Humans
    135. Locke FL, Zha YY, Zheng Y, Driessens G, Gajewski TF. Conditional deletion of PTEN in peripheral T cells augments TCR-mediated activation but does not abrogate CD28 dependency or prevent anergy induction. J Immunol. 2013 Aug 15; 191(4):1677-85. PMID: 23851688; PMCID: PMC3759681.
      Citations: 10     Fields:    Translation:AnimalsCells
    136. Geynisman DM, Zha Y, Kunnavakkam R, Aklilu M, Catenacci DV, Polite BN, Rosenbaum C, Namakydoust A, Karrison T, Gajewski TF, Kindler HL. A randomized pilot phase I study of modified carcinoembryonic antigen (CEA) peptide (CAP1-6D)/montanide/GM-CSF-vaccine in patients with pancreatic adenocarcinoma. J Immunother Cancer. 2013; 1:8. PMID: 24829746; PMCID: PMC4019890.
      Citations: 19     Fields:    
    137. Hodi FS, Corless CL, Giobbie-Hurder A, Fletcher JA, Zhu M, Marino-Enriquez A, Friedlander P, Gonzalez R, Weber JS, Gajewski TF, O'Day SJ, Kim KB, Lawrence D, Flaherty KT, Luke JJ, Collichio FA, Ernstoff MS, Heinrich MC, Beadling C, Zukotynski KA, Yap JT, Van den Abbeele AD, Demetri GD, Fisher DE. Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin. J Clin Oncol. 2013 Sep 10; 31(26):3182-90. PMID: 23775962; PMCID: PMC4878082.
      Citations: 191     Fields:    Translation:HumansCTClinical Trials
    138. Ascierto PA, Grimaldi AM, Acquavella N, Borgognoni L, Cascinelli N, Cesano A, Del Vecchio M, Eggermont AM, Faries M, Ferrone S, Fox BA, Gajewski TF, Gnjatic S, Gogas H, Kashani-Sabet M, Kaufman HL, Larkin J, Lo RS, Mantovani A, Margolin K, Melief C, McArthur G, Palmieri G, Puzanov I, Ribas A, Seliger B, Sosman J, Suenaert P, Tarhini AA, Trinchieri G, Vidal-Vanaclocha F, Wang E, Ciliberto G, Mozzillo N, Marincola FM, Thurin M, Calabrò L, Galon J. Future perspectives in melanoma research. Meeting report from the "Melanoma Bridge. Napoli, December 2nd-4th 2012". J Transl Med. 2013 Jun 03; 11:137. PMID: 23731854; PMCID: PMC3681569.
      Citations: 12     Fields:    Translation:HumansAnimals
    139. Zhang L, Chen X, Liu X, Kline DE, Teague RM, Gajewski TF, Kline J. CD40 ligation reverses T cell tolerance in acute myeloid leukemia. J Clin Invest. 2013 May; 123(5):1999-2010. PMID: 23619361; PMCID: PMC3635717.
      Citations: 47     Fields:    Translation:AnimalsCells
    140. Gajewski TF, Schumacher T. Cancer immunotherapy. Curr Opin Immunol. 2013 Apr; 25(2):259-60. PMID: 23587868.
      Citations: 9     Fields:    Translation:HumansCells
    141. Gajewski TF, Woo SR, Zha Y, Spaapen R, Zheng Y, Corrales L, Spranger S. Cancer immunotherapy strategies based on overcoming barriers within the tumor microenvironment. Curr Opin Immunol. 2013 Apr; 25(2):268-76. PMID: 23579075.
      Citations: 214     Fields:    Translation:Humans
    142. Zheng Y, Zha Y, Spaapen RM, Mathew R, Barr K, Bendelac A, Gajewski TF. Egr2-dependent gene expression profiling and ChIP-Seq reveal novel biologic targets in T cell anergy. Mol Immunol. 2013 Oct; 55(3-4):283-91. PMID: 23548837; PMCID: PMC3646929.
      Citations: 26     Fields:    Translation:AnimalsCells
    143. Gajewski TF, Salama AK, Niedzwiecki D, Johnson J, Linette G, Bucher C, Blaskovich MA, Sebti SM, Haluska F, Cancer and Leukemia Group B. Phase II study of the farnesyltransferase inhibitor R115777 in advanced melanoma (CALGB 500104). J Transl Med. 2012 Dec 10; 10:246. PMID: 23228035; PMCID: PMC3543225.
      Citations: 34     Fields:    Translation:HumansCellsCTClinical Trials
    144. Gangadhar TC, Clark JI, Karrison T, Gajewski TF. Phase II study of the Src kinase inhibitor saracatinib (AZD0530) in metastatic melanoma. Invest New Drugs. 2013 Jun; 31(3):769-73. PMID: 23151808; PMCID: PMC3600382.
      Citations: 30     Fields:    Translation:HumansCellsCTClinical Trials
    145. Zheng Y, Zha Y, Driessens G, Locke F, Gajewski TF. Transcriptional regulator early growth response gene 2 (Egr2) is required for T cell anergy in vitro and in vivo. J Exp Med. 2012 Nov 19; 209(12):2157-63. PMID: 23129747; PMCID: PMC3501351.
      Citations: 64     Fields:    Translation:HumansAnimalsCells
    146. Fuertes MB, Woo SR, Burnett B, Fu YX, Gajewski TF. Type I interferon response and innate immune sensing of cancer. Trends Immunol. 2013 Feb; 34(2):67-73. PMID: 23122052; PMCID: PMC3565059.
      Citations: 177     Fields:    Translation:HumansAnimalsCells
    147. Marincola FM, Angell HK, Thurin M, Lugli A, Zlobec I, Berger A, Bifulco C, Botti G, Tatangelo F, Britten CM, Kreiter S, Chouchane L, Delrio P, Arndt H, Asslaber M, Maio M, Masucci GV, Mihm M, Vidal-Vanaclocha F, Allison JP, Gnjatic S, Hakansson L, Huber C, Singh-Jasuja H, Ottensmeier C, Zwierzina H, Laghi L, Grizzi F, Ohashi PS, Shaw PA, Clarke BA, Wouters BG, Kawakami Y, Hazama S, Okuno K, Wang E, O'Donnell-Tormey J, Lagorce C, Pawelec G, Nishimura MI, Hawkins R, Lundqvist A, Khleif SN, Ogino S, Gibbs P, Waring P, Sato N, Torigoe T, Itoh K, Patel PS, Shukla SN, Palmqvist R, Nagtegaal ID, Wang Y, D'Arrigo C, Kopetz S, Sinicrope FA, Trinchieri G, Gajewski TF, Ascierto PA, Fox BA, Galon J, Pagès F, Lapointe R. Cancer classification using the Immunoscore: a worldwide task force. J Transl Med. 2012 Oct 03; 10:205. PMID: 23034130; PMCID: PMC3554496.
      Citations: 380     Fields:    Translation:Humans
    148. Cohen EE, Wu K, Hartford C, Kocherginsky M, Eaton KN, Zha Y, Nallari A, Maitland ML, Fox-Kay K, Moshier K, House L, Ramirez J, Undevia SD, Fleming GF, Gajewski TF, Ratain MJ. Phase I studies of sirolimus alone or in combination with pharmacokinetic modulators in advanced cancer patients. Clin Cancer Res. 2012 Sep 01; 18(17):4785-93. PMID: 22872575; PMCID: PMC4410974.
      Citations: 31     Fields:    Translation:HumansAnimalsCTClinical Trials
    149. Ascierto PA, Grimaldi AM, Curti B, Faries MB, Ferrone S, Flaherty K, Fox BA, Gajewski TF, Gershenwald JE, Gogas H, Grossmann K, Hauschild A, Hodi FS, Kefford R, Kirkwood JM, Leachmann S, Maio M, Marais R, Palmieri G, Morton DL, Ribas A, Stroncek DF, Stewart R, Wang E, Mozzillo N, Marincola FM. Future perspectives in melanoma research. Meeting report from the "Melanoma research: a bridge from Naples to the World. Napoli, December 5th-6th 2011". J Transl Med. 2012 Jul 04; 10:83. PMID: 22551296; PMCID: PMC3390271.
      Citations: 4     Fields:    Translation:HumansAnimals
    150. Gajewski TF, Fuertes MB, Woo SR. Innate immune sensing of cancer: clues from an identified role for type I IFNs. Cancer Immunol Immunother. 2012 Aug; 61(8):1343-7. PMID: 22722449.
      Citations: 23     Fields:    Translation:HumansAnimalsCells
    151. Martinez Forero I, Okada H, Topalian SL, Gajewski TF, Korman AJ, Melero I. Workshop on immunotherapy combinations. Society for Immunotherapy of Cancer annual meeting Bethesda, November 3, 2011. J Transl Med. 2012 May 28; 10:108. PMID: 22640522; PMCID: PMC3404934.
      Citations: 6     Fields:    Translation:HumansAnimals
    152. Kline J, Zhang L, Battaglia L, Cohen KS, Gajewski TF. Cellular and molecular requirements for rejection of B16 melanoma in the setting of regulatory T cell depletion and homeostatic proliferation. J Immunol. 2012 Mar 15; 188(6):2630-42. PMID: 22312128; PMCID: PMC3294164.
      Citations: 25     Fields:    Translation:AnimalsCells
    153. Shakur SF, Takagi I, Lukas RV, Chmura S, Gajewski TF, Roitberg BZ. Ocular melanoma metastasis to the cervical spine. J Clin Neurosci. 2012 Apr; 19(4):610-1. PMID: 22245271.
      Citations: 3     Fields:    Translation:Humans
    154. Gajewski TF. Cancer immunotherapy. Mol Oncol. 2012 Apr; 6(2):242-50. PMID: 22248437; PMCID: PMC3345039.
      Citations: 37     Fields:    Translation:Humans
    155. Marincola FM, Thurin M, Trinchieri G, Fox BA, Gajewski TF, Ascierto PA, Galon J, Pagès F. The immune score as a new possible approach for the classification of cancer. J Transl Med. 2012 Jan 03; 10:1. PMID: 22214470; PMCID: PMC3269368.
      Citations: 275     Fields:    Translation:Humans
    156. Gajewski T. Harnessing the immune response. Clin Adv Hematol Oncol. 2012 Jan; 10(1):46-8. PMID: 22398808.
      Citations:    Fields:    Translation:Humans
    157. Fox BA, Schendel DJ, Butterfield LH, Aamdal S, Allison JP, Ascierto PA, Atkins MB, Bartunkova J, Bergmann L, Berinstein N, Bonorino CC, Borden E, Bramson JL, Britten CM, Cao X, Carson WE, Chang AE, Characiejus D, Choudhury AR, Coukos G, de Gruijl T, Dillman RO, Dolstra H, Dranoff G, Durrant LG, Finke JH, Galon J, Gollob JA, Grizzi F, Guida M, Hege K, Herberman RB, Hodi FS, Hoos A, Huber C, Hwu P, Imai K, Jaffee EM, Janetzki S, June CH, Kalinski P, Kaufman HL, Kawakami K, Kawakami Y, Keilholtz U, Khleif SN, Kiessling R, Kotlan B, Kroemer G, Lapointe R, Levitsky HI, Lotze MT, Maccalli C, Maio M, Marschner JP, Mastrangelo MJ, Masucci G, Melero I, Melief C, Murphy WJ, Nelson B, Nicolini A, Nishimura MI, Odunsi K, Ohashi PS, O'Donnell-Tormey J, Old LJ, Ottensmeier C, Papamichail M, Parmiani G, Pawelec G, Proietti E, Qin S, Rees R, Ribas A, Ridolfi R, Ritter G, Rivoltini L, Romero PJ, Salem ML, Scheper RJ, Seliger B, Sharma P, Shiku H, Singh-Jasuja H, Song W, Straten PT, Tahara H, Tian Z, van Der Burg SH, von Hoegen P, Wang E, Welters MJ, Winter H, Withington T, Wolchok JD, Xiao W, Zitvogel L, Zwierzina H, Marincola FM, Gajewski TF, Wigginton JM, Disis ML, Gouttefangeas C, Håkansson L. Defining the critical hurdles in cancer immunotherapy. J Transl Med. 2011 Dec 14; 9:214. PMID: 22168571; PMCID: PMC3338100.
      Citations: 71     Fields:    Translation:Humans
    158. Bedognetti D, Balwit JM, Wang E, Disis ML, Britten CM, Delogu LG, Tomei S, Fox BA, Gajewski TF, Marincola FM, Butterfield LH. SITC/iSBTc Cancer Immunotherapy Biomarkers Resource Document: online resources and useful tools - a compass in the land of biomarker discovery. J Transl Med. 2011 Sep 19; 9:155. PMID: 21929757; PMCID: PMC3189883.
      Citations: 14     Fields:    Translation:Humans
    159. Fuertes MB, Kacha AK, Kline J, Woo SR, Kranz DM, Murphy KM, Gajewski TF. Host type I IFN signals are required for antitumor CD8+ T cell responses through CD8{alpha}+ dendritic cells. J Exp Med. 2011 Sep 26; 208(10):2005-16. PMID: 21930765; PMCID: PMC3182064.
      Citations: 601     Fields:    Translation:HumansAnimalsCells
    160. Janardhan SV, Praveen K, Marks R, Gajewski TF. Evidence implicating the Ras pathway in multiple CD28 costimulatory functions in CD4+ T cells. PLoS One. 2011; 6(9):e24931. PMID: 21949793; PMCID: PMC3176298.
      Citations: 14     Fields:    Translation:AnimalsCells
    161. Balwit JM, Kalinski P, Sondak VK, Coulie PG, Jaffee EM, Gajewski TF, Marincola FM. Review of the 25th annual scientific meeting of the International Society for Biological Therapy of Cancer. J Transl Med. 2011 May 12; 9:60. PMID: 21569425; PMCID: PMC3115875.
      Citations: 1     Fields:    Translation:Humans
    162. Gajewski TF. Molecular profiling of melanoma and the evolution of patient-specific therapy. Semin Oncol. 2011 Apr; 38(2):236-42. PMID: 21421113; PMCID: PMC3073764.
      Citations: 7     Fields:    Translation:Humans
    163. Gajewski TF, Fuertes M, Spaapen R, Zheng Y, Kline J. Molecular profiling to identify relevant immune resistance mechanisms in the tumor microenvironment. Curr Opin Immunol. 2011 Apr; 23(2):286-92. PMID: 21185705; PMCID: PMC3070788.
      Citations: 73     Fields:    Translation:HumansAnimalsCells
    164. Driessens G, Zheng Y, Locke F, Cannon JL, Gounari F, Gajewski TF. Beta-catenin inhibits T cell activation by selective interference with linker for activation of T cells-phospholipase C-?1 phosphorylation. J Immunol. 2011 Jan 15; 186(2):784-90. PMID: 21149602; PMCID: PMC4888792.
      Citations: 31     Fields:    Translation:AnimalsCells
    165. Kline J, Gajewski TF. Clinical development of mAbs to block the PD1 pathway as an immunotherapy for cancer. Curr Opin Investig Drugs. 2010 Dec; 11(12):1354-9. PMID: 21154117.
      Citations: 37     Fields:    Translation:HumansAnimalsCells
    166. Gajewski TF. Improved melanoma survival at last! Ipilimumab and a paradigm shift for immunotherapy. Pigment Cell Melanoma Res. 2010 Oct; 23(5):580-1. PMID: 20609175.
      Citations: 3     Fields:    Translation:Humans
    167. Kline J, Grinblatt D, Zimmerman T, Conner K, Muhs C, Gajewski T, Van Besien K, Smith SM, Poiré X. Phase II study of immunomodulation with granulocyte-macrophage colony-stimulating factor, interleukin-2, and rituximab following autologous stem cell transplant in patients with relapsed or refractory lymphomas. Leuk Lymphoma. 2010 Jul; 51(7):1241-50. PMID: 20496994.
      Citations: 5     Fields:    Translation:HumansCTClinical Trials
    168. Gajewski TF, Louahed J, Brichard VG. Gene signature in melanoma associated with clinical activity: a potential clue to unlock cancer immunotherapy. Cancer J. 2010 Jul-Aug; 16(4):399-403. PMID: 20693853.
      Citations: 129     Fields:    Translation:HumansAnimals
    169. Driessens G, Zheng Y, Gajewski TF. Beta-catenin does not regulate memory T cell phenotype. Nat Med. 2010 May; 16(5):513-4; author reply 514-5. PMID: 20448567.
      Citations: 24     Fields:    Translation:Animals
    170. O'Day SJ, Maio M, Chiarion-Sileni V, Gajewski TF, Pehamberger H, Bondarenko IN, Queirolo P, Lundgren L, Mikhailov S, Roman L, Verschraegen C, Humphrey R, Ibrahim R, de Pril V, Hoos A, Wolchok JD. Efficacy and safety of ipilimumab monotherapy in patients with pretreated advanced melanoma: a multicenter single-arm phase II study. Ann Oncol. 2010 Aug; 21(8):1712-1717. PMID: 20147741.
      Citations: 212     Fields:    Translation:HumansCTClinical Trials
    171. Takacs Z, Toups M, Kollewe A, Johnson E, Cuello LG, Driessens G, Biancalana M, Koide A, Ponte CG, Perozo E, Gajewski TF, Suarez-Kurtz G, Koide S, Goldstein SA. A designer ligand specific for Kv1.3 channels from a scorpion neurotoxin-based library. Proc Natl Acad Sci U S A. 2009 Dec 29; 106(52):22211-6. PMID: 20007782; PMCID: PMC2799710.
      Citations: 29     Fields:    Translation:HumansAnimalsCells
    172. Schuster K, Gadiot J, Andreesen R, Mackensen A, Gajewski TF, Blank C. Homeostatic proliferation of naïve CD8+ T cells depends on CD62L/L-selectin-mediated homing to peripheral LN. Eur J Immunol. 2009 Nov; 39(11):2981-90. PMID: 19658092.
      Citations: 9     Fields:    Translation:AnimalsCells
    173. Locke F, Clark JI, Gajewski TF. A phase II study of oxaliplatin, docetaxel, and GM-CSF in patients with previously treated advanced melanoma. Cancer Chemother Pharmacol. 2010 Feb; 65(3):509-14. PMID: 19597729.
      Citations: 7     Fields:    Translation:HumansCTClinical Trials
    174. Molinero LL, Yang J, Gajewski T, Abraham C, Farrar MA, Alegre ML. CARMA1 controls an early checkpoint in the thymic development of FoxP3+ regulatory T cells. J Immunol. 2009 Jun 01; 182(11):6736-43. PMID: 19454668; PMCID: PMC2830151.
      Citations: 62     Fields:    Translation:AnimalsCells
    175. Praveen K, Zheng Y, Rivas F, Gajewski TF. Protein kinase Ctheta focusing at the cSMAC is a consequence rather than cause of TCR signaling and is dependent on the MEK/ERK pathway. J Immunol. 2009 May 15; 182(10):6022-30. PMID: 19414753.
      Citations: 2     Fields:    Translation:AnimalsCells
    176. Zhang L, Gajewski TF, Kline J. PD-1/PD-L1 interactions inhibit antitumor immune responses in a murine acute myeloid leukemia model. Blood. 2009 Aug 20; 114(8):1545-52. PMID: 19417208; PMCID: PMC2731636.
      Citations: 194     Fields:    Translation:HumansAnimalsCells
    177. Driessens G, Kline J, Gajewski TF. Costimulatory and coinhibitory receptors in anti-tumor immunity. Immunol Rev. 2009 May; 229(1):126-44. PMID: 19426219; PMCID: PMC3278040.
      Citations: 130     Fields:    Translation:HumansAnimalsCells
    178. Harlin H, Meng Y, Peterson AC, Zha Y, Tretiakova M, Slingluff C, McKee M, Gajewski TF. Chemokine expression in melanoma metastases associated with CD8+ T-cell recruitment. Cancer Res. 2009 Apr 01; 69(7):3077-85. PMID: 19293190; PMCID: PMC3886718.
      Citations: 584     Fields:    Translation:HumansCells
    179. Knight D, Peterson AC, Rini BI, Harlin H, Gajewski TF, Stadler WM. The HLA-A2-restricted PSMA peptide LLHETDSAV is poorly immunogenic in patients with metastatic prostate cancer. Prostate. 2009 Feb 01; 69(2):142-8. PMID: 18942640.
      Citations: 3     Fields:    Translation:HumansCells
    180. Camacho LH, Antonia S, Sosman J, Kirkwood JM, Gajewski TF, Redman B, Pavlov D, Bulanhagui C, Bozon VA, Gomez-Navarro J, Ribas A. Phase I/II trial of tremelimumab in patients with metastatic melanoma. J Clin Oncol. 2009 Mar 01; 27(7):1075-81. PMID: 19139427.
      Citations: 109     Fields:    Translation:HumansCTClinical Trials
    181. Gajewski TF, Chesney J, Curriel TJ. Emerging strategies in regulatory T-cell immunotherapies. Clin Adv Hematol Oncol. 2009 Jan; 7(1):1-10; quiz 11-2. PMID: 19288606.
      Citations: 3     Fields:    Translation:HumansAnimalsCells
    182. Gordon IO, Wade T, Chin K, Dickstein J, Gajewski TF. Immune-mediated red cell aplasia after anti-CTLA-4 immunotherapy for metastatic melanoma. Cancer Immunol Immunother. 2009 Aug; 58(8):1351-3. PMID: 19052742.
      Citations: 33     Fields:    Translation:Humans
    183. Cham CM, Driessens G, O'Keefe JP, Gajewski TF. Glucose deprivation inhibits multiple key gene expression events and effector functions in CD8+ T cells. Eur J Immunol. 2008 Sep; 38(9):2438-50. PMID: 18792400; PMCID: PMC3008428.
      Citations: 218     Fields:    Translation:AnimalsCells
    184. Lee RT, Fallarino F, Ashikari A, Gajewski TF. Melanoma presenting as circulating tumor cells associated with failed angiogenesis. Melanoma Res. 2008 Aug; 18(4):289-94. PMID: 18626315.
      Citations: 1     Fields:    Translation:HumansAnimalsCells
    185. O'Day SJ, Ibrahim R, DePril V, Maio M, Chiarion-Sileni V, Gajewski TF, Pehamberger H, Hoos A, Humphrey R, Wolchock J. Efficacy and safety of ipilimumab induction and maintenance dosing in patients with advanced melanoma who progressed on one or more prior therapies. J Clin Oncol. 2008 May 20; 26(15_suppl):9021. PMID: 27950718.
    186. Kline J, Brown IE, Zha YY, Blank C, Strickler J, Wouters H, Zhang L, Gajewski TF. Homeostatic proliferation plus regulatory T-cell depletion promotes potent rejection of B16 melanoma. Clin Cancer Res. 2008 May 15; 14(10):3156-67. PMID: 18483384.
      Citations: 56     Fields:    Translation:AnimalsCells
    187. Harlin H, Gajewski TF. Diagnosis and treatment of mycoplasma-contaminated cell cultures. Curr Protoc Cytom. 2008 Jan; Appendix 3:Appendix 3C. PMID: 18770641.
      Citations: 6     Fields:    Translation:Cells
    188. Zheng Y, Zha Y, Gajewski TF. Molecular regulation of T-cell anergy. EMBO Rep. 2008 Jan; 9(1):50-5. PMID: 18174897; PMCID: PMC2246614.
      Citations: 48     Fields:    Translation:HumansAnimalsCells
    189. Zha Y, Shah R, Locke F, Wong A, Gajewski TF. Use of Cre-adenovirus and CAR transgenic mice for efficient deletion of genes in post-thymic T cells. J Immunol Methods. 2008 Feb 29; 331(1-2):94-102. PMID: 18177887; PMCID: PMC3278801.
      Citations: 7     Fields:    Translation:AnimalsCells
    190. Zha Y, Gajewski TF. An adenoviral vector encoding dominant negative Cbl lowers the threshold for T cell activation in post-thymic T cells. Cell Immunol. 2007 Jun; 247(2):95-102. PMID: 17897636; PMCID: PMC3286639.
      Citations: 8     Fields:    Translation:AnimalsCells
    191. Gajewski TF. Failure at the effector phase: immune barriers at the level of the melanoma tumor microenvironment. Clin Cancer Res. 2007 Sep 15; 13(18 Pt 1):5256-61. PMID: 17875753.
      Citations: 112     Fields:    Translation:HumansCells
    192. Atkins MB, Carbone D, Coukos G, Dhodapkar M, Ernstoff MS, Finke J, Gajewski TF, Gollob J, Lotze MT, Storkus W, Weiner LM. Report on the ISBTC mini-symposium on biologic effects of targeted therapeutics. J Immunother. 2007 Sep; 30(6):577-90. PMID: 17667521.
      Citations: 1     Fields:    Translation:Humans
    193. Gajewski TF. The expanding universe of regulatory T cell subsets in cancer. Immunity. 2007 Aug; 27(2):185-7. PMID: 17723212.
      Citations: 11     Fields:    Translation:HumansAnimalsCells
    194. Yu P, Lee Y, Wang Y, Liu X, Auh S, Gajewski TF, Schreiber H, You Z, Kaynor C, Wang X, Fu YX. Targeting the primary tumor to generate CTL for the effective eradication of spontaneous metastases. J Immunol. 2007 Aug 01; 179(3):1960-8. PMID: 17641063; PMCID: PMC2387226.
      Citations: 43     Fields:    Translation:HumansAnimalsCells
    195. Marks RE, Ho AW, Robbel C, Kuna T, Berk S, Gajewski TF. Farnesyltransferase inhibitors inhibit T-cell cytokine production at the posttranscriptional level. Blood. 2007 Sep 15; 110(6):1982-8. PMID: 17545504; PMCID: PMC1976355.
      Citations: 15     Fields:    Translation:HumansCells
    196. Gajewski TF. On the TRAIL toward death receptor-based cancer therapeutics. J Clin Oncol. 2007 Apr 10; 25(11):1305-7. PMID: 17416849.
      Citations: 8     Fields:    Translation:HumansAnimals
    197. Zha Y, Marks R, Ho AW, Peterson AC, Janardhan S, Brown I, Praveen K, Stang S, Stone JC, Gajewski TF. T cell anergy is reversed by active Ras and is regulated by diacylglycerol kinase-alpha. Nat Immunol. 2006 Nov; 7(11):1166-73. PMID: 17028589.
      Citations: 142     Fields:    Translation:AnimalsCells
    198. Brown IE, Blank C, Kline J, Kacha AK, Gajewski TF. Homeostatic proliferation as an isolated variable reverses CD8+ T cell anergy and promotes tumor rejection. J Immunol. 2006 Oct 01; 177(7):4521-9. PMID: 16982889.
      Citations: 48     Fields:    Translation:AnimalsCells
    199. Gajewski TF, Meng Y, Blank C, Brown I, Kacha A, Kline J, Harlin H. Immune resistance orchestrated by the tumor microenvironment. Immunol Rev. 2006 Oct; 213:131-45. PMID: 16972901.
      Citations: 215     Fields:    Translation:HumansAnimalsCells
    200. Meng Y, Harlin H, O'Keefe JP, Gajewski TF. Induction of cytotoxic granules in human memory CD8+ T cell subsets requires cell cycle progression. J Immunol. 2006 Aug 01; 177(3):1981-7. PMID: 16849512.
      Citations: 19     Fields:    Translation:HumansCells
    201. Blank C, Kuball J, Voelkl S, Wiendl H, Becker B, Walter B, Majdic O, Gajewski TF, Theobald M, Andreesen R, Mackensen A. Blockade of PD-L1 (B7-H1) augments human tumor-specific T cell responses in vitro. Int J Cancer. 2006 Jul 15; 119(2):317-27. PMID: 16482562.
      Citations: 128     Fields:    Translation:HumansCells
    202. Fitch FW, Gajewski TF, Hu-Li J. Production of TH1 and TH2 cell lines and clones. Curr Protoc Immunol. 2006 May; Chapter 3:Unit 3.13. PMID: 18432972.
      Citations: 17     Fields:    Translation:HumansAnimalsCells
    203. Gajewski TF, Meng Y, Harlin H. Immune suppression in the tumor microenvironment. J Immunother. 2006 May-Jun; 29(3):233-40. PMID: 16699366.
      Citations: 104     Fields:    Translation:HumansAnimalsCellsPHPublic Health
    204. Atkins MB, Elder DE, Essner R, Flaherty KT, Gajewski TF, Haluska FG, Hwu P, Keilholz U, Kirkwood JM, Mier JW, Ross MI, Slingluff CL, Sondak VK, Sosman JA, Weinstock MA, King L. Innovations and challenges in melanoma: summary statement from the first Cambridge conference. Clin Cancer Res. 2006 Apr 01; 12(7 Pt 2):2291s-2296s. PMID: 16609047.
      Citations:    Fields:    Translation:Humans
    205. Gajewski TF. Identifying and overcoming immune resistance mechanisms in the melanoma tumor microenvironment. Clin Cancer Res. 2006 Apr 01; 12(7 Pt 2):2326s-2330s. PMID: 16609053.
      Citations: 34     Fields:    Translation:HumansAnimalsCells
    206. Peterson AC, Harlin H, Karrison T, Vogelzang NJ, Knost JA, Kugler JW, Lester E, Vokes E, Gajewski TF, Stadler WM, University of Chicago Phase II Consortium. A randomized phase II trial of interleukin-2 in combination with four different doses of bryostatin-1 in patients with renal cell carcinoma. Invest New Drugs. 2006 Mar; 24(2):141-9. PMID: 16514482.
      Citations: 9     Fields:    Translation:HumansCellsCTClinical Trials
    207. Velicu S, Han Y, Ulasov I, Brown IE, El Andaloussi A, Gajewski TF, Lesniak MS. Cross-priming of T cells to intracranial tumor antigens elicits an immune response that fails in the effector phase but can be augmented with local immunotherapy. J Neuroimmunol. 2006 May; 174(1-2):74-81. PMID: 16504307.
      Citations: 3     Fields:    Translation:AnimalsCells
    208. Tripathi P, Madan R, Chougnet C, Divanovic S, Ma X, Wahl LM, Gajewski T, Karp CL, Hildeman DA. An adenoviral vector for probing promoter activity in primary immune cells. J Immunol Methods. 2006 Apr 20; 311(1-2):19-30. PMID: 16563424; PMCID: PMC2964867.
      Citations: 2     Fields:    Translation:HumansAnimalsCells
    209. Harlin H, Kuna TV, Peterson AC, Meng Y, Gajewski TF. Tumor progression despite massive influx of activated CD8(+) T cells in a patient with malignant melanoma ascites. Cancer Immunol Immunother. 2006 Oct; 55(10):1185-97. PMID: 16468035.
      Citations: 50     Fields:    Translation:HumansCells
    210. Harlin H, Gajewski TF. Diagnosis and treatment of Mycoplasma-contaminated cell cultures. Curr Protoc Microbiol. 2006 Jan; Appendix 3:Appendix 3B. PMID: 18770568.
      Citations:    Fields:    Translation:Cells
    211. Roberts JD, Niedzwiecki D, Carson WE, Chapman PB, Gajewski TF, Ernstoff MS, Hodi FS, Shea C, Leong SP, Johnson J, Zhang D, Houghton A, Haluska FG, Cancer and Leukemia Group B. Phase 2 study of the g209-2M melanoma peptide vaccine and low-dose interleukin-2 in advanced melanoma: Cancer and Leukemia Group B 509901. J Immunother. 2006 Jan-Feb; 29(1):95-101. PMID: 16365605.
      Citations: 4     Fields:    Translation:HumansCellsCTClinical Trials
    212. O'Keefe JP, Gajewski TF. Cutting edge: cytotoxic granule polarization and cytolysis can occur without central supramolecular activation cluster formation in CD8+ effector T cells. J Immunol. 2005 Nov 01; 175(9):5581-5. PMID: 16237042.
      Citations: 22     Fields:    Translation:AnimalsCells
    213. Gajewski TF, Sosman J, Gerson SL, Liu L, Dolan E, Lin S, Vokes EE. Phase II trial of the O6-alkylguanine DNA alkyltransferase inhibitor O6-benzylguanine and 1,3-bis(2-chloroethyl)-1-nitrosourea in advanced melanoma. Clin Cancer Res. 2005 Nov 01; 11(21):7861-5. PMID: 16278409.
      Citations: 22     Fields:    Translation:HumansCellsCTClinical Trials
    214. Margolin K, Longmate J, Baratta T, Synold T, Christensen S, Weber J, Gajewski T, Quirt I, Doroshow JH. CCI-779 in metastatic melanoma: a phase II trial of the California Cancer Consortium. Cancer. 2005 Sep 01; 104(5):1045-8. PMID: 16007689.
      Citations: 80     Fields:    Translation:HumansCTClinical Trials
    215. Redman BG, Ernstoff MS, Gajewski TF, Cunningham C, Lawson DH, Gregoire L, Haltom E, Uprichard MJ. Phase 2 trial of talabostat in stage IV melanoma. J Clin Oncol. 2005 Jun; 23(16_suppl):7570. PMID: 27946035.
    216. Gajewski TF, Peterson AC, Slingluff C, McKee M, Harlin H. Reciprocal expression of indoleamine-2,3-dioxygenase (IDO) and arginase-I in metastatic melanoma tumors. J Clin Oncol. 2005 Jun; 23(16_suppl):7523. PMID: 27946220.
    217. Cham CM, Gajewski TF. Glucose availability regulates IFN-gamma production and p70S6 kinase activation in CD8+ effector T cells. J Immunol. 2005 Apr 15; 174(8):4670-7. PMID: 15814691.
      Citations: 187     Fields:    Translation:AnimalsCells
    218. Blank C, Brown I, Kacha AK, Markiewicz MA, Gajewski TF. ICAM-1 contributes to but is not essential for tumor antigen cross-priming and CD8+ T cell-mediated tumor rejection in vivo. J Immunol. 2005 Mar 15; 174(6):3416-20. PMID: 15749875.
      Citations: 14     Fields:    Translation:AnimalsCells
    219. Gajewski TF. Lymphoma-infiltrating immune cells. N Engl J Med. 2005 Feb 17; 352(7):724-5; author reply 724-5. PMID: 15719444.
      Citations:    Fields:    Translation:HumansCells
    220. Artz AS, Van Besien K, Zimmerman T, Gajewski TF, Rini BI, Hu HS, Stadler WM, Vogelzang NJ. Long-term follow-up of nonmyeloablative allogeneic stem cell transplantation for renal cell carcinoma: The University of Chicago Experience. Bone Marrow Transplant. 2005 Feb; 35(3):253-60. PMID: 15543195.
      Citations: 8     Fields:    Translation:HumansCTClinical Trials
    221. Brown IE, Mashayekhi M, Markiewicz M, Alegre ML, Gajewski TF. Peripheral survival of naïve CD8+ T cells. Apoptosis. 2005 Jan; 10(1):5-11. PMID: 15711917.
      Citations: 4     Fields:    Translation:HumansAnimalsCells
    222. Cham CM, Gajewski TF. Metabolic mechanisms of tumor resistance to T cell effector function. Immunol Res. 2005; 31(2):107-18. PMID: 15778509.
      Citations: 8     Fields:    Translation:HumansAnimalsCells
    223. Blank C, Gajewski TF, Mackensen A. Interaction of PD-L1 on tumor cells with PD-1 on tumor-specific T cells as a mechanism of immune evasion: implications for tumor immunotherapy. Cancer Immunol Immunother. 2005 Apr; 54(4):307-14. PMID: 15599732.
      Citations: 242     Fields:    Translation:HumansAnimalsCells
    224. Zimmerman TM, Harlin H, Odenike OM, Berk S, Sprague E, Karrison T, Stock W, Larson RA, Ratain MJ, Gajewski TF. Dose-ranging pharmacodynamic study of tipifarnib (R115777) in patients with relapsed and refractory hematologic malignancies. J Clin Oncol. 2004 Dec 01; 22(23):4816-22. PMID: 15570084.
      Citations: 11     Fields:    Translation:HumansCTClinical Trials
    225. Gajewski TF. Overcoming immune resistance in the tumor microenvironment by blockade of indoleamine 2,3-dioxygenase and programmed death ligand 1. Curr Opin Investig Drugs. 2004 Dec; 5(12):1279-83. PMID: 15648949.
      Citations:    Fields:    Translation:HumansAnimals
    226. Medved M, Karczmar G, Yang C, Dignam J, Gajewski TF, Kindler H, Vokes E, MacEneany P, Mitchell MT, Stadler WM. Semiquantitative analysis of dynamic contrast enhanced MRI in cancer patients: Variability and changes in tumor tissue over time. J Magn Reson Imaging. 2004 Jul; 20(1):122-8. PMID: 15221817.
      Citations: 46     Fields:    Translation:HumansCTClinical Trials
    227. Aklilu M, Stadler WM, Markiewicz M, Vogelzang NJ, Mahowald M, Johnson M, Gajewski TF. Depletion of normal B cells with rituximab as an adjunct to IL-2 therapy for renal cell carcinoma and melanoma. Ann Oncol. 2004 Jul; 15(7):1109-14. PMID: 15205206.
      Citations: 30     Fields:    Translation:HumansCellsCTClinical Trials
    228. Peterson AC, Swiger S, Stadler WM, Medved M, Karczmar G, Gajewski TF. Phase II study of the Flk-1 tyrosine kinase inhibitor SU5416 in advanced melanoma. Clin Cancer Res. 2004 Jun 15; 10(12 Pt 1):4048-54. PMID: 15217937.
      Citations: 16     Fields:    Translation:HumansCellsCTClinical Trials
    229. O'Keefe JP, Blaine K, Alegre ML, Gajewski TF. Formation of a central supramolecular activation cluster is not required for activation of naive CD8+ T cells. Proc Natl Acad Sci U S A. 2004 Jun 22; 101(25):9351-6. PMID: 15192143; PMCID: PMC438980.
      Citations: 19     Fields:    Translation:AnimalsCells
    230. Harlin H, Artz AS, Mahowald M, Rini BI, Zimmerman T, Vogelzang NJ, Gajewski TF. Clinical responses following nonmyeloablative allogeneic stem cell transplantation for renal cell carcinoma are associated with expansion of CD8+ IFN-gamma-producing T cells. Bone Marrow Transplant. 2004 Mar; 33(5):491-7. PMID: 14716341.
      Citations: 6     Fields:    Translation:HumansCellsCTClinical Trials
    231. Gajewski TF. Update on vaccines for solid tumors. Clin Adv Hematol Oncol. 2004 Mar; 2(3):158-9. PMID: 16166944.
      Citations:    Fields:    Translation:Humans
    232. Blank C, Brown I, Peterson AC, Spiotto M, Iwai Y, Honjo T, Gajewski TF. PD-L1/B7H-1 inhibits the effector phase of tumor rejection by T cell receptor (TCR) transgenic CD8+ T cells. Cancer Res. 2004 Feb 01; 64(3):1140-5. PMID: 14871849.
      Citations: 346     Fields:    Translation:AnimalsCells
    233. Rivas FV, O'Keefe JP, Alegre ML, Gajewski TF. Actin cytoskeleton regulates calcium dynamics and NFAT nuclear duration. Mol Cell Biol. 2004 Feb; 24(4):1628-39. PMID: 14749378; PMCID: PMC344175.
      Citations: 32     Fields:    Translation:AnimalsCells
    234. Gajewski TF. Temozolomide for melanoma: new toxicities and new opportunities. J Clin Oncol. 2004 Feb 15; 22(4):580-1. PMID: 14726506.
      Citations: 2     Fields:    Translation:Humans
    235. Zha Yy, Blank C, Gajewski TF. Negative regulation of T-cell function by PD-1. Crit Rev Immunol. 2004; 24(4):229-37. PMID: 15588223.
      Citations: 33     Fields:    Translation:HumansAnimalsCells
    236. Marks RE, Ho AW, Rivas F, Marshall E, Janardhan S, Gajewski TF. Differential Ras signaling via the antigen receptor and IL-2 receptor in primary T lymphocytes. Biochem Biophys Res Commun. 2003 Dec 19; 312(3):691-6. PMID: 14680820.
      Citations: 10     Fields:    Translation:AnimalsCells
    237. Blank C, Brown I, Marks R, Nishimura H, Honjo T, Gajewski TF. Absence of programmed death receptor 1 alters thymic development and enhances generation of CD4/CD8 double-negative TCR-transgenic T cells. J Immunol. 2003 Nov 01; 171(9):4574-81. PMID: 14568931.
      Citations: 43     Fields:    Translation:AnimalsCells
    238. Markiewicz MA, Brown I, Gajewski TF. Death of peripheral CD8+ T cells in the absence of MHC class I is Fas-dependent and not blocked by Bcl-xL. Eur J Immunol. 2003 Oct; 33(10):2917-26. PMID: 14515276.
      Citations: 12     Fields:    Translation:AnimalsCells
    239. Peterson AC, Marks RE, Fields PE, Imamoto A, Gajewski TF. T cell development and function in CrkL-deficient mice. Eur J Immunol. 2003 Oct; 33(10):2687-95. PMID: 14515252.
      Citations: 5     Fields:    Translation:AnimalsCells
    240. Tschoep K, Manning TC, Harlin H, George C, Johnson M, Gajewski TF. Disparate functions of immature and mature human myeloid dendritic cells: implications for dendritic cell-based vaccines. J Leukoc Biol. 2003 Jul; 74(1):69-80. PMID: 12832444.
      Citations: 6     Fields:    Translation:HumansCells
    241. Liu X, Gao JX, Wen J, Yin L, Li O, Zuo T, Gajewski TF, Fu YX, Zheng P, Liu Y. B7DC/PDL2 promotes tumor immunity by a PD-1-independent mechanism. J Exp Med. 2003 Jun 16; 197(12):1721-30. PMID: 12810690; PMCID: PMC2193953.
      Citations: 49     Fields:    Translation:AnimalsCells
    242. Peterson AC, Harlin H, Gajewski TF. Immunization with Melan-A peptide-pulsed peripheral blood mononuclear cells plus recombinant human interleukin-12 induces clinical activity and T-cell responses in advanced melanoma. J Clin Oncol. 2003 Jun 15; 21(12):2342-8. PMID: 12805336.
      Citations: 44     Fields:    Translation:HumansCellsCTClinical Trials
    243. Cham CM, Xu H, O'Keefe JP, Rivas FV, Zagouras P, Gajewski TF. Gene array and protein expression profiles suggest post-transcriptional regulation during CD8+ T cell differentiation. J Biol Chem. 2003 May 09; 278(19):17044-52. PMID: 12582156.
      Citations: 11     Fields:    Translation:AnimalsCells
    244. Winegarden JD, Mauer AM, Gajewski TF, Hoffman PC, Krauss S, Rudin CM, Vokes EE. A phase II study of bryostatin-1 and paclitaxel in patients with advanced non-small cell lung cancer. Lung Cancer. 2003 Feb; 39(2):191-6. PMID: 12581572.
      Citations: 12     Fields:    Translation:HumansCellsCTClinical Trials
    245. Spiotto MT, Yu P, Rowley DA, Nishimura MI, Meredith SC, Gajewski TF, Fu YX, Schreiber H. Increasing tumor antigen expression overcomes "ignorance" to solid tumors via crosspresentation by bone marrow-derived stromal cells. Immunity. 2002 Dec; 17(6):737-47. PMID: 12479820.
      Citations: 90     Fields:    Translation:AnimalsCells
    246. Hwang KW, Sweatt WB, Brown IE, Blank C, Gajewski TF, Bluestone JA, Alegre ML. Cutting edge: targeted ligation of CTLA-4 in vivo by membrane-bound anti-CTLA-4 antibody prevents rejection of allogeneic cells. J Immunol. 2002 Jul 15; 169(2):633-7. PMID: 12097362.
      Citations: 8     Fields:    Translation:AnimalsCells
    247. Rini BI, Paintal A, Vogelzang NJ, Gajewski TF, Stadler WM. Flt-3 ligand and sequential FL/interleukin-2 in patients with metastatic renal carcinoma: clinical and biologic activity. J Immunother. 2002 May-Jun; 25(3):269-77. PMID: 12000869.
      Citations: 6     Fields:    Translation:HumansCellsCTClinical Trials
    248. Rini BI, Zimmerman T, Stadler WM, Gajewski TF, Vogelzang NJ, Rini BI, Zimmerman T, Stadler WM, Gajewski TF, Vogelzang NJ. Allogeneic stem-cell transplantation of renal cell cancer after nonmyeloablative chemotherapy: feasibility, engraftment, and clinical results. J Clin Oncol. 2002 Apr 15; 20(8):2017-24. PMID: 11956260.
      Citations: 22     Fields:    Translation:HumansCTClinical Trials
    249. Gajewski TF. Integrating IL-12 into therapeutic cancer vaccines. Cancer Chemother Biol Response Modif. 2002; 20:343-9. PMID: 12703213.
      Citations: 1     Fields:    Translation:HumansAnimalsCells
    250. Rivas FV, O'Herrin S, Gajewski TF. CD28 is not required for c-Jun N-terminal kinase activation in T cells. J Immunol. 2001 Sep 15; 167(6):3123-8. PMID: 11544297.
      Citations: 11     Fields:    Translation:AnimalsCells
    251. O'Herrin SM, Slansky JE, Tang Q, Markiewicz MA, Gajewski TF, Pardoll DM, Schneck JP, Bluestone JA, O'Herrin SM, Slansky JE, Tang Q, Markiewicz MA, Gajewski TF, Pardoll DM, Schneck JP, Bluestone JA. Antigen-specific blockade of T cells in vivo using dimeric MHC peptide. J Immunol. 2001 Sep 01; 167(5):2555-60. PMID: 11509595.
      Citations: 23     Fields:    Translation:HumansAnimalsCells
    252. Markiewicz MA, Fallarino F, Ashikari A, Gajewski TF. Epitope spreading upon P815 tumor rejection triggered by vaccination with the single class I MHC-restricted peptide P1A. Int Immunol. 2001 May; 13(5):625-32. PMID: 11312250.
      Citations: 14     Fields:    Translation:AnimalsCells
    253. Gajewski TF, Markiewicz MA, Uyttenhove C. The p815 mastocytoma tumor model. Curr Protoc Immunol. 2001 May; Chapter 20:Unit 20.4. PMID: 18432777.
      Citations: 7     Fields:    Translation:HumansAnimalsCells
    254. Fitch FW, Gajewski TF, Yokoyama WM. Diagnosis and treatment of mycoplasma-contaminated cell cultures. Curr Protoc Immunol. 2001 May; Appendix 3:Appendix 3E. PMID: 18432657.
      Citations:    Fields:    Translation:Cells
    255. Rini BI, Zimmerman TM, Gajewski TF, Stadler WM, Vogelzang NJ. Allogeneic peripheral blood stem cell transplantation for metastatic renal cell carcinoma. J Urol. 2001 Apr; 165(4):1208-9. PMID: 11257677.
      Citations: 1     Fields:    Translation:Humans
    256. Gajewski TF, Fallarino F, Fields PE, Rivas F, Alegre ML. Absence of CTLA-4 lowers the activation threshold of primed CD8+ TCR-transgenic T cells: lack of correlation with Src homology domain 2-containing protein tyrosine phosphatase. J Immunol. 2001 Mar 15; 166(6):3900-7. PMID: 11238634.
      Citations: 12     Fields:    Translation:AnimalsCellsPHPublic Health
    257. Gajewski TF, Fallarino F, Ashikari A, Sherman M. Immunization of HLA-A2+ melanoma patients with MAGE-3 or MelanA peptide-pulsed autologous peripheral blood mononuclear cells plus recombinant human interleukin 12. Clin Cancer Res. 2001 Mar; 7(3 Suppl):895s-901s. PMID: 11300489.
      Citations: 24     Fields:    Translation:HumansCellsCTClinical Trials
    258. Alegre M, Fallarino F, Zhou P, Frauwirth K, Thistlethwaite J, Newell K, Gajewski T, Bluestone J. Transplantation and the CD28/CTLA4/B7 pathway. Transplant Proc. 2001 Feb-Mar; 33(1-2):209-11. PMID: 11266782.
      Citations: 5     Fields:    Translation:HumansAnimalsCells
    259. Wan YY, Leon RP, Marks R, Cham CM, Schaack J, Gajewski TF, DeGregori J. Transgenic expression of the coxsackie/adenovirus receptor enables adenoviral-mediated gene delivery in naive T cells. Proc Natl Acad Sci U S A. 2000 Dec 05; 97(25):13784-9. PMID: 11095726; PMCID: PMC17653.
      Citations: 43     Fields:    Translation:HumansAnimalsCells
    260. Kacha AK, Fallarino F, Markiewicz MA, Gajewski TF. Cutting edge: spontaneous rejection of poorly immunogenic P1.HTR tumors by Stat6-deficient mice. J Immunol. 2000 Dec 01; 165(11):6024-8. PMID: 11086033.
      Citations: 28     Fields:    Translation:AnimalsCells
    261. Griffin MD, Hong DK, Holman PO, Lee KM, Whitters MJ, O'Herrin SM, Fallarino F, Collins M, Segal DM, Gajewski TF, Kranz DM, Bluestone JA. Blockade of T cell activation using a surface-linked single-chain antibody to CTLA-4 (CD152). J Immunol. 2000 May 01; 164(9):4433-42. PMID: 10779742.
      Citations: 19     Fields:    Translation:HumansAnimalsCells
    262. Gajewski TF. Monitoring specific T-cell responses to melanoma vaccines: ELISPOT, tetramers, and beyond. Clin Diagn Lab Immunol. 2000 Mar; 7(2):141-4. PMID: 10702484; PMCID: PMC95840.
      Citations: 6     Fields:    Translation:HumansCells
    263. Fields PE, Gajewski TF. Biochemical analysis of activated T lymphocytes. Protein phosphorylation and Ras, ERK, and JNK activation. Methods Mol Biol. 2000; 134:307-17. PMID: 10730269.
      Citations: 5     Fields:    Translation:HumansCells
    264. Fallarino F, Gajewski TF. Cutting edge: differentiation of antitumor CTL in vivo requires host expression of Stat1. J Immunol. 1999 Oct 15; 163(8):4109-13. PMID: 10510345.
      Citations: 25     Fields:    Translation:AnimalsCellsPHPublic Health
    265. Rini BI, Gajewski TF. Polymyositis with respiratory muscle weakness requiring mechanical ventilation in a patient with metastatic thymoma treated with octreotide. Ann Oncol. 1999 Aug; 10(8):973-9. PMID: 10509161.
      Citations: 3     Fields:    Translation:Humans
    266. Detremmerie O, Giannouli C, Thielemans K, Gajewski TF, Burny A, Leo O, Hallez S. Interleukin-12-secreting human papillomavirus type 16-transformed cells provide a potent cancer vaccine that generates E7-directed immunity. Int J Cancer. 1999 May 05; 81(3):428-37. PMID: 10209958.
      Citations: 7     Fields:    Translation:AnimalsCells
    267. Fallarino F, Uyttenhove C, Boon T, Gajewski TF. Improved efficacy of dendritic cell vaccines and successful immunization with tumor antigen peptide-pulsed peripheral blood mononuclear cells by coadministration of recombinant murine interleukin-12. Int J Cancer. 1999 Jan 18; 80(2):324-33. PMID: 9935218.
      Citations: 4     Fields:    Translation:HumansAnimalsCellsPHPublic Health
    268. Markiewicz MA, Gajewski TF. The immune system as anti-tumor sentinel: molecular requirements for an anti-tumor immune response. Crit Rev Oncog. 1999; 10(3):247-60. PMID: 10468184.
      Citations: 16     Fields:    Translation:HumansAnimalsCells
    269. Fields PE, Finch RJ, Gray GS, Zollner R, Thomas JL, Sturmhoefel K, Lee K, Wolf S, Gajewski TF, Fitch FW. B7.1 is a quantitatively stronger costimulus than B7.2 in the activation of naive CD8+ TCR-transgenic T cells. J Immunol. 1998 Nov 15; 161(10):5268-75. PMID: 9820499.
      Citations: 13     Fields:    Translation:HumansAnimalsCells
    270. Alegre ML, Shiels H, Thompson CB, Gajewski TF. Expression and function of CTLA-4 in Th1 and Th2 cells. J Immunol. 1998 Oct 01; 161(7):3347-56. PMID: 9759851.
      Citations: 50     Fields:    Translation:AnimalsCells
    271. Bird JJ, Brown DR, Mullen AC, Moskowitz NH, Mahowald MA, Sider JR, Gajewski TF, Wang CR, Reiner SL. Helper T cell differentiation is controlled by the cell cycle. Immunity. 1998 Aug; 9(2):229-37. PMID: 9729043.
      Citations: 242     Fields:    Translation:AnimalsCells
    272. Fallarino F, Fields PE, Gajewski TF. B7-1 engagement of cytotoxic T lymphocyte antigen 4 inhibits T cell activation in the absence of CD28. J Exp Med. 1998 Jul 06; 188(1):205-10. PMID: 9653097; PMCID: PMC2525552.
      Citations: 49     Fields:    Translation:AnimalsCells
    273. Manning TC, Rund LA, Gruber MM, Fallarino F, Gajewski TF, Kranz DM. Antigen recognition and allogeneic tumor rejection in CD8+ TCR transgenic/RAG(-/-) mice. J Immunol. 1997 Nov 15; 159(10):4665-75. PMID: 9366389.
      Citations: 11     Fields:    Translation:AnimalsCells
    274. Fallarino F, Ashikari A, Boon T, Gajewski TF. Antigen-specific regression of established tumors induced by active immunization with irradiated IL-12- but not B7-1-transfected tumor cells. Int Immunol. 1997 Sep; 9(9):1259-69. PMID: 9310829.
      Citations: 6     Fields:    Translation:AnimalsCells
    275. Godfraind C, Amar-Costesec A, Renauld JC, Gajewski TF, Duffour MT, Warnier G, Boon T, Van den Eynde BJ, Uyttenhove C, Lethé B. The expression of mouse gene P1A in testis does not prevent safe induction of cytolytic T cells against a P1A-encoded tumor antigen. Int J Cancer. 1997 Jan 27; 70(3):349-56. PMID: 9033639.
      Citations: 19     Fields:    Translation:AnimalsCells
    276. Gajewski TF, Thompson CB. Apoptosis meets signal transduction: elimination of a BAD influence. Cell. 1996 Nov 15; 87(4):589-92. PMID: 8929527.
      Citations: 48     Fields:    Translation:Cells
    277. Fields P, Fitch FW, Gajewski TF. Control of T lymphocyte signal transduction through clonal anergy. J Mol Med (Berl). 1996 Nov; 74(11):673-83. PMID: 8956153.
      Citations: 8     Fields:    Translation:Cells
    278. Warnier G, Duffour MT, Uyttenhove C, Gajewski TF, Lurquin C, Haddada H, Perricaudet M, Boon T. Induction of a cytolytic T-cell response in mice with a recombinant adenovirus coding for tumor antigen P815A. Int J Cancer. 1996 Jul 17; 67(2):303-10. PMID: 8760603.
      Citations: 4     Fields:    Translation:HumansAnimalsCellsPHPublic Health
    279. Gajewski TF, Fallarino F, Uyttenhove C, Boon T. Tumor rejection requires a CTLA4 ligand provided by the host or expressed on the tumor: superiority of B7-1 over B7-2 for active tumor immunization. J Immunol. 1996 Apr 15; 156(8):2909-17. PMID: 8609411.
      Citations: 19     Fields:    Translation:AnimalsCells
    280. Fields PE, Gajewski TF, Fitch FW. Blocked Ras activation in anergic CD4+ T cells. Science. 1996 Mar 01; 271(5253):1276-8. PMID: 8638108.
      Citations: 103     Fields:    Translation:AnimalsCells
    281. Fallarino F, Uyttenhove C, Boon T, Gajewski TF. Endogenous IL-12 is necessary for rejection of P815 tumor variants in vivo. J Immunol. 1996 Feb 01; 156(3):1095-100. PMID: 8557984.
      Citations: 19     Fields:    Translation:AnimalsCells
    282. Gajewski TF. B7-1 but not B7-2 efficiently costimulates CD8+ T lymphocytes in the P815 tumor system in vitro. J Immunol. 1996 Jan 15; 156(2):465-72. PMID: 8543795.
      Citations: 16     Fields:    Translation:AnimalsCells
    283. Gajewski TF, Fallarino F. Rational development of tumour antigen-specific immunization in melanoma. Ther Immunol. 1995 Aug; 2(4):211-25. PMID: 9358613.
      Citations: 2     Fields:    Translation:HumansAnimalsCellsPHPublic Health
    284. Boon T, Gajewski TF, Coulie PG. From defined human tumor antigens to effective immunization? Immunol Today. 1995 Jul; 16(7):334-6. PMID: 7576068.
      Citations: 21     Fields:    Translation:HumansAnimalsPHPublic Health
    285. Gajewski TF, Fields P, Fitch FW. Induction of the increased Fyn kinase activity in anergic T helper type 1 clones requires calcium and protein synthesis and is sensitive to cyclosporin A. Eur J Immunol. 1995 Jul; 25(7):1836-42. PMID: 7621861.
      Citations: 15     Fields:    Translation:AnimalsCells
    286. Gajewski TF, Renauld JC, Van Pel A, Boon T. Costimulation with B7-1, IL-6, and IL-12 is sufficient for primary generation of murine antitumor cytolytic T lymphocytes in vitro. J Immunol. 1995 Jun 01; 154(11):5637-48. PMID: 7538528.
      Citations: 17     Fields:    Translation:AnimalsCells
    287. Lancki DW, Qian D, Fields P, Gajewski T, Fitch FW. Differential requirement for protein tyrosine kinase Fyn in the functional activation of antigen-specific T lymphocyte clones through the TCR or Thy-1. J Immunol. 1995 May 01; 154(9):4363-70. PMID: 7722293.
      Citations: 5     Fields:    Translation:AnimalsCells
    288. Bastin J, Gajewski T, Coulie PG, De Smet C, Traversari C, Townsend A, Boon T, van der Bruggen P, Boël P. A peptide encoded by human gene MAGE-3 and presented by HLA-A2 induces cytolytic T lymphocytes that recognize tumor cells expressing MAGE-3. Eur J Immunol. 1994 Dec; 24(12):3038-43. PMID: 7805731.
      Citations: 75     Fields:    Translation:HumansCells
    289. Gajewski TF, Lancki DW, Stack R, Fitch FW. "Anergy" of TH0 helper T lymphocytes induces downregulation of TH1 characteristics and a transition to a TH2-like phenotype. J Exp Med. 1994 Feb 01; 179(2):481-91. PMID: 8294862; PMCID: PMC2191376.
      Citations: 38     Fields:    Translation:HumansAnimalsCells
    290. Gajewski TF, Qian D, Fields P, Fitch FW. Anergic T-lymphocyte clones have altered inositol phosphate, calcium, and tyrosine kinase signaling pathways. Proc Natl Acad Sci U S A. 1994 Jan 04; 91(1):38-42. PMID: 7506419; PMCID: PMC42881.
      Citations: 35     Fields:    Translation:AnimalsCells
    291. Fabry Z, Sandor M, Gajewski TF, Herlein JA, Waldschmidt MM, Lynch RG, Hart MN. Differential activation of Th1 and Th2 CD4+ cells by murine brain microvessel endothelial cells and smooth muscle/pericytes. J Immunol. 1993 Jul 01; 151(1):38-47. PMID: 8100844.
      Citations: 18     Fields:    Translation:AnimalsCells
    292. Fitch FW, McKisic MD, Lancki DW, Gajewski TF. Differential regulation of murine T lymphocyte subsets. Annu Rev Immunol. 1993; 11:29-48. PMID: 8476563.
      Citations: 52     Fields:    Translation:AnimalsCells
    293. Magilavy DB, Foys KM, Gajewski TF. Liver of MRL/lpr mice contain interleukin-4-producing lymphocytes and accessory cells that support the proliferation of Th2 helper T lymphocyte clones. Eur J Immunol. 1992 Sep; 22(9):2359-65. PMID: 1387611.
      Citations: 5     Fields:    Translation:AnimalsCells
    294. Barrett TA, Gajewski TF, Danielpour D, Chang EB, Beagley KW, Bluestone JA. Differential function of intestinal intraepithelial lymphocyte subsets. J Immunol. 1992 Aug 15; 149(4):1124-30. PMID: 1380032.
      Citations: 46     Fields:    Translation:AnimalsCells
    295. Gold MR, Gajewski TF, DeFranco AL. Regulation of anti-immunoglobulin-induced B lymphoma growth arrest by transforming growth factor beta 1 and dexamethasone. Int Immunol. 1991 Nov; 3(11):1091-8. PMID: 1760404.
      Citations:    Fields:    Translation:AnimalsCells
    296. Gajewski TF, Pinnas M, Wong T, Fitch FW. Murine Th1 and Th2 clones proliferate optimally in response to distinct antigen-presenting cell populations. J Immunol. 1991 Mar 15; 146(6):1750-8. PMID: 1826010.
      Citations: 87     Fields:    Translation:AnimalsCells
    297. Gajewski TF, Fitch FW. Differential activation of murine TH1 and TH2 clones. Res Immunol. 1991 Jan; 142(1):19-23. PMID: 1829255.
      Citations: 7     Fields:    Translation:AnimalsCells
    298. Sandor M, Gajewski T, Thorson J, Kemp JD, Fitch FW, Lynch RG. CD4+ murine T cell clones that express high levels of immunoglobulin binding belong to the interleukin 4-producing T helper cell type 2 subset. J Exp Med. 1990 Jun 01; 171(6):2171-6. PMID: 1972182; PMCID: PMC2187953.
      Citations: 9     Fields:    Translation:AnimalsCells
    299. Gajewski TF, Schell SR, Fitch FW. Evidence implicating utilization of different T cell receptor-associated signaling pathways by TH1 and TH2 clones. J Immunol. 1990 Jun 01; 144(11):4110-20. PMID: 2140386.
      Citations: 52     Fields:    Translation:AnimalsCells
    300. Gajewski TF, Fitch FW. Anti-proliferative effect of IFN-gamma in immune regulation. IV. Murine CTL clones produce IL-3 and GM-CSF, the activity of which is masked by the inhibitory action of secreted IFN-gamma. J Immunol. 1990 Jan 15; 144(2):548-56. PMID: 2104898.
      Citations: 12     Fields:    Translation:AnimalsCells
    301. Gajewski TF, Schell SR, Nau G, Fitch FW. Regulation of T-cell activation: differences among T-cell subsets. Immunol Rev. 1989 Oct; 111:79-110. PMID: 2534116.
      Citations: 54     Fields:    Translation:HumansCells
    302. Magilavy DB, Fitch FW, Gajewski TF. Murine hepatic accessory cells support the proliferation of Th1 but not Th2 helper T lymphocyte clones. J Exp Med. 1989 Sep 01; 170(3):985-90. PMID: 2527946; PMCID: PMC2189453.
      Citations: 15     Fields:    Translation:AnimalsCells
    303. Gajewski TF, Joyce J, Fitch FW. Antiproliferative effect of IFN-gamma in immune regulation. III. Differential selection of TH1 and TH2 murine helper T lymphocyte clones using recombinant IL-2 and recombinant IFN-gamma. J Immunol. 1989 Jul 01; 143(1):15-22. PMID: 2525146.
      Citations: 94     Fields:    Translation:AnimalsCells
    304. Cron RQ, Gajewski TF, Sharrow SO, Fitch FW, Matis LA, Bluestone JA. Phenotypic and functional analysis of murine CD3+,CD4-,CD8- TCR-gamma delta-expressing peripheral T cells. J Immunol. 1989 Jun 01; 142(11):3754-62. PMID: 2523934.
      Citations: 29     Fields:    Translation:AnimalsCells
    305. Gajewski TF, Goldwasser E, Fitch FW. Anti-proliferative effect of IFN-gamma in immune regulation. II. IFN-gamma inhibits the proliferation of murine bone marrow cells stimulated with IL-3, IL-4, or granulocyte-macrophage colony-stimulating factor. J Immunol. 1988 Oct 15; 141(8):2635-42. PMID: 2971726.
      Citations: 19     Fields:    Translation:AnimalsCells
    306. Gajewski TF, Fitch FW. Anti-proliferative effect of IFN-gamma in immune regulation. I. IFN-gamma inhibits the proliferation of Th2 but not Th1 murine helper T lymphocyte clones. J Immunol. 1988 Jun 15; 140(12):4245-52. PMID: 2967332.
      Citations: 213     Fields:    Translation:AnimalsCells
    307. Fitch F, Gajewski T, Nau G, Schell S, Otten G. Nakahara memorial lecture. Regulation of T lymphocyte responses: interactions among receptors. Princess Takamatsu Symp. 1988; 19:15-27. PMID: 2978617.
      Citations:    Fields:    Translation:HumansAnimalsCells
    308. Dunn DE, Herold KC, Otten GR, Lancki DW, Gajewski T, Vogel SN, Fitch FW. Interleukin 2 and concanavalin A stimulate interferon-gamma production in a murine cytolytic T cell clone by different pathways. J Immunol. 1987 Dec 15; 139(12):3942-8. PMID: 3121725.
      Citations: 4     Fields:    Translation:AnimalsCells
    309. Ma DI, Wilde DB, Gajewski T, Dunn DE, Fitch FW. Evidence implicating I region-restricted antigen presentation in alloantigen and nominal antigen recognition by a dual-reactive helper T lymphocyte clone. J Immunol. 1984 Sep; 133(3):1101-10. PMID: 6235280.
      Citations: 1     Fields:    Translation:AnimalsCells
    310. Broda R, Gajewski T, Krzok J. [Case of foreign body in the brain]. Wiad Lek. 1979 Dec 15; 32(24):1777-9. PMID: 545900.
      Citations:    Fields:    Translation:Humans
    311. Rogalski E, Wyrwa E, Gajewski T. [Use of valvular drainage of the pleural cavity in the treatment of spontaneous pneumothorax]. Pol Przegl Chir. 1972 Aug; 44(8):1373-7. PMID: 5070946.
      Citations:    Fields:    Translation:Humans
    312. Gajewski T, Tylicki C. [2- and multistage surgical procedures on the intestines]. Pol Przegl Chir. 1967 Dec; 39(12):1277-80. PMID: 5594258.
      Citations:    Fields:    Translation:Humans
    313. GAJEWSKI T. [Osteoid osteoma]. Pol Przegl Chir. 1962 Jul; 34:721-3. PMID: 13946179.
      Citations:    Fields:    Translation:Humans
    314. GAJEWSKI T, JEZEWSKA D. [A case of effusion of chyle into the pleural and peritoneal cavity]. Pediatr Pol. 1962 Feb; 37:183-6. PMID: 13896281.
      Citations:    Fields:    Translation:Humans
    315. GAJEWSKI T, GOLAB W. [Perthes' syndrome after crushing of the thorax]. Pol Tyg Lek. 1961 Jan 16; 16:94-6. PMID: 13702984.
      Citations:    Fields:    Translation:Humans
    316. GAJEWSKI T, KUSMIERSKI S. [Parotitis as a postoperative complication]. Pol Tyg Lek. 1959 Nov 30; 14:2117-9. PMID: 13825979.
      Citations:    Fields:    
    317. GAJEWSKI T. [Indications concerning the management of patients with artificial anus]. Pol Tyg Lek. 1959 Jun 29; 14:1212-4. PMID: 13825980.
      Citations:    Fields:    Translation:Humans
    318. GAJEWSKI T. [Surgical treatment of a case of giant hypertrophy of the mandible]. Pol Tyg Lek (Wars). 1956 Apr 23; 11(17):751-4. PMID: 13349730.
    Gajewski's Networks
    Click the
    buttons for more information and interactive visualizations!
    Concepts (855)
    Co-Authors (97)
    Similar People (60)
    Same Department Expand Description
    Physical Neighbors